

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**

---

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

**EP 0 965 637 A1**

(12)

**EUROPEAN PATENT APPLICATION**

published in accordance with Art. 158(3) EPC

(43) Date of publication:

22.12.1999 Bulletin 1999/51

(21) Application number: 97918354.8

(22) Date of filing: 01.05.1997

(51) Int. Cl.<sup>6</sup>: **C12N 15/12**, C12N 15/62,  
C07K 14/47, C12P 21/02,  
C12N 1/21, A61K 38/16

(86) International application number:  
**PCT/JP97/01502**

(87) International publication number:  
**WO 97/42319 (13.11.1997 Gazette 1997/49)**

*EP 16051*

(84) Designated Contracting States:

**AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC  
NL PT SE**

(30) Priority: 02.05.1996 JP 13576096

(71) Applicants:

- **MOCHIDA PHARMACEUTICAL CO., LTD.**  
Shinjuku-ku, Tokyo 160-0004 (JP)
- **OSAKA BIOSCIENCE INSTITUTE**  
Suita-shi, Osaka-Fu 565 (JP)

(72) Inventors:

- **NAKAMURA, Norio**,  
Mochida Pharmaceutical Co., Ltd.  
Tokyo 160 (JP)
- **NAGATA, Shigekazu**  
Suita-shi, Osaka-fu 565 (JP)

(74) Representative:

**Grünecker, Kinkeldey,  
Stockmair & Schwanhäusser  
Anwaltssozietät  
Maximilianstrasse 58  
80538 München (DE)**

**(54) Fas ANTIGEN DERIVATIVES**

(57) This invention provides a novel Fas antigen derivative which comprises at least a part or entire portion of Fas antigen extracellular region polypeptide in which at least one amino acid residue is deleted from a group of amino acid residues starting from the N-terminal amino acid residue of the Fas antigen polypeptide to a cysteine residue most close to the N-terminal side (excluding said cysteine residue), as well as a DNA fragment which encodes said Fas antigen derivative, a recombinant DNA molecule which contains said DNA sequence, a transformant in which said recombinant DNA molecule is introduced, a method for the production of said Fas antigen derivative, a medicament which contains said novel Fas antigen derivative as the active ingredient and a method for the improvement of activities and functions of Fas antigen and the like.

**EP 0 965 637 A1**

## Description

## TECHNICAL FIELD

- 5 [0001] This invention provides the field of medicaments with a novel Fas antigen derivative in which its activities and the like are improved and with a novel DNA fragment which encodes the same. The present invention also provides a recombinant DNA molecule which contains said DNA fragment, a transformant and a method for the production of said novel Fas antigen derivative.

## 10 BACKGROUND ART

[0002] Human Fas antigen is a polypeptide which is distributed in the surface of various cells and considered to be related to a type of the death of cells, called apoptosis. Homeostasis of the living body is skillfully regulated by the growth and differentiation of cells and the death thereof, and apoptosis is a mode of cell death which is discriminated from necrosis among modes of dying cells. It is known that the death of cells required for the maintenance of homeostasis of the living body, namely a case of cell death in which cells unnecessary for the living body are removed or virus-infected cells or tumor cells are attacked and removed by cytotoxic T lymphocytes (CTL) or natural killer (NK) cells, is mainly based on apoptosis.

[0003] It has been remained unexplained for a long time about the true character of Fas antigen which is a monoclonal antibody obtained by immunizing mice with human fibroblasts, originally found by Yonehara, S. *et al.* (*J. Exp. Med.*, vol. 169, pp. 1747 - 1756, 1989) as a cell surface antigen which is recognized by an anti-Fas antibody capable of inducing apoptosis in certain cells (Yonehara, S. *et al.*) and transfers a signal of apoptosis to the cells.

[0004] Recently, a Fas antigen gene has been cloned which revealed that the Fas antigen is a type I transmembrane glycoprotein which, according to its amino acid sequence, belongs to the NGFR (nerve growth factor receptor)/TNFR (TNF receptor) family that constitutes physiologically important cell surface membrane proteins (Itoh, N. *et al.*, *Cell*, vol. 66, pp. 233 - 243, 1991). A mouse Fas antigen gene has also been cloned (Watanabe-Fukunaga, R. *et al.*, *J. Immunol.*, vol. 148, pp. 1274 - 1279, 1992), which confirmed that Fas antigen mRNA is expressed in the thymus, liver, lung, heart and ovary of mouse. Its expression in human has also been reported in various tissues and cells such as lymphocytes, hepatocytes, small intestine epithelial cells, skin keratinocytes and osteoblasts (Leithauser, F. *et al.*, *Lab. Invest.*, vol. 69, pp. 415 - 429, 1993).

[0005] The Fas antigen which was originally assumed to be present on the surface of cells has been detected in blood and culture supernatants, too, and its presence in the form of a soluble type Fas antigen (sFas) has also been found, so that their physiological functions and the like have become of interest in recent years.

[0006] Cheng, J. *et al.* (*Science*, vol. 263, pp. 1759 - 1762, 1994) have reported that they have found a mRNA molecule coding for a  $\Delta$ TM type soluble form of Fas antigen, which seemed to encode a secretor molecule by the deletion of exon IV (corresponds to 14 base pairs of the extracellular region and 49 base pairs of the transmembrane region) due to alternative splicing, that concentration of the soluble type Fas antigen was high in sera of systemic lupus erythematosus (SLE) patients and that increase in the autologous mixed lymphocyte reaction was observed, together with increase in the number of splenocytes, when a chimera molecule composed of the extracellular region of mouse Fas antigen and the Fc moiety of human IgG was administered to mice. Also, Cascino, I. *et al.* (*J. Immunol.*, vol. 154, pp. 2706 - 2713, 1995) have reported that at least three Fas antigen-encoding mRNA molecules exist, including the just described Fas antigen mRNA. Though their physiological functions, expression regions and the like are still unclear, it has been shown that the recombinant  $\Delta$ TM type Fas antigen inhibits the cytotoxic activity of Fas ligand in a concentration-dependent manner and that most of the soluble type Fas antigens existing in sera of healthy people and SLE patients are  $\Delta$ TM type Fas antigens encoded by splicing variants (Kayagaki, N. *et al.*, *Igaku-no Ayumi* (Advance in Medical Science), vol. 174, pp. 1136 - 1140, 1995).

[0007] In addition, Kimura, K. *et al.* have recently cloned a rat Fas antigen gene and reported that two types of Fas antigen mRNA can be detected in rat liver mRNA based on the alternative splicing and that a mRNA molecule which encodes a peptide having smaller molecular weight is present in addition to the mRNA of membrane binding type Fas antigen (*Biochemical and Biophysical Research Communications*, vol. 198 (2), pp. 666 - 674 (1994)) and also have isolated and identified mutants (variants) of corresponding human Fas antigen (Japanese Patent Application Kokai No. 7-289266).

[0008] On the other hand, human Fas ligand is a polypeptide that has been reported by Nagata *et al.* to be a biological molecule that induces apoptosis of Fas antigen-expressing cells (Takahashi, T. *et al.*, *International Immunology*, vol. 6, pp. 1567 - 1574, 1994). Human Fas ligand is a Type II membrane protein of TNF family with a molecular weight of about 40 kD. As in the case of TNF, human Fas ligand in the human body is estimated to be in the form of a trimer (Tanaka, M. *et al.*, *EMBO Journal*, vol. 14, pp. 1129 - 1135, 1995). The extracellular domain of the human Fas ligand is highly homologous with the extracellular domain of rat Fas ligand (Suda, T. *et al.*, *Cell*, vol. 75, pp. 1169 - 1178, 1993) and

mouse Fas ligand (Takahashi, T. *et al.*, *Cell*, vol. 76, pp. 969-976, 1994). The human Fas ligand recognizes not only human Fas antigen but also mouse Fas antigen, and induces the apoptosis. On the other hand, the rat Fas ligand and the mouse Fas ligand recognize the human Fas antigen to induce the apoptosis.

[0009] Apoptosis has called attention for its deep involvement in homeostasis of an organism. The homology of the Fas ligands among different species as mentioned above suggests the important role of the apoptosis mediated by the Fas ligand and the Fas antigen in the homeostasis of organism.

[0010] Recently, an interesting relation of abnormality of Fas ligand and Fas antigen with an autoimmune disease has been reported. In this report, there is suggested that MRL-lpr/lpr (a strain of model mouse for an autoimmune disease) has mutation in its Fas antigen gene, and apoptosis is not induced in the cells expressing such mutant Fas antigen gene (Watanabe-Fukunaga, R. *et al.*, *Nature*, vol. 356, pp. 314 - 317, 1993; Adachi, M. *et al.*, *Proc. Natl. Acad. Sci. USA*, vol. 90, 1993). In the meanwhile, there has also been reported that C3H-gld/gld (another strain of model mouse for an autoimmune disease) has mutation in its Fas ligand gene, and that the Fas ligand of the gld mouse has no apoptosis-inducing activity. The mutation in the Fas ligand gene of the gld mouse is a point mutation, and as a result of such point mutation, 7th amino acid from the C terminal of the extracellular domain of the Fas ligand is replaced with another amid acid (Tomohiro Takahashi, *et al.*, *Cell*, vol. 76, pp. 969 - 976, 1994). The Fas ligand of the gld mouse as described above is incapable of binding with the Fas antigen (Fred Ramsdell, *et al.*, *Eur. J. Immunol.*, vol. 24, pp. 928 - 933, 1994).

[0011] Also, in the case of SLE patients, increase in the level of a soluble type Fas antigen in blood (Cheng J. *et al.*, *Science*, vol. 263, pp. 1759 - 1762, 1994) and increase in the expression of a Fas antigen on the surface of lymphocytes (Amasaki T. *et al.*, *Clin. Exp. Immunol.*, vol. 99, pp. 245 - 250, 1995) have been reported, and it has been suggested about a possibility that abnormality of a Fas antigen gene accompanied by the abnormal expression and function of the Fas antigen is concerned also in lymphocytosis syndrome (Rieux Laucat *et al.*, *Science*, vol. 268, pp. 1347 - 1349, 1995, and Fisher G.H. *et al.*, *Cell*, vol. 81, pp. 935 - 946, 1995).

[0012] The finding as described above resulted in the hypothesis that some autoimmune diseases are induced by the abnormality of the Fas antigen or the Fas ligand, namely, by the autoreactive T cells remaining in the body that should have been removed from the body by undergoing apoptosis if the cells had been normal.

[0013] Recently, it is conceived that abnormal propagation and articular cytolysis of synovial membrane that takes place in articular rheumatism is also induced by the failure of normal apoptosis of the cell. Kobayashi, N. *et al.* further estimates that reduction in the number of T cells upon infection by AIDS virus is mediated by the Fas ligand since expression of the Fas antigen on the T cell membrane is induced upon infection by the AIDS virus (*Nikkei Science*, vol. 6, pp. 34 - 41, 1993).

[0014] Participation of apoptosis by Fas ligand has been suggested also in viral fulminant hepatitis and the like diseases (Nagata, S. *et al.*, *Immunol. Today*, vol. 16, pp. 39 - 43, 1995). Thus, as the relationship between Fas antigen-mediated apoptosis and diseases has been revealed, great concern has been directed toward the application of Fas ligand or Fas antigen to the treatment of diseases which are accompanied by abnormal apoptosis, namely the aforementioned autoimmune diseases, rheumatism, AIDS and the like.

[0015] Examples of the substance which inhibits Fas antigen-mediated apoptosis so far reported include a  $\Delta$  TM type Fas antigen, a fusion protein of the extracellular region of Fas antigen with the Fc region of immunoglobulin G (IgG) and a fragment of anti-Fas antibody (Dhein J. *et al.*, *Nature*, vol. 373, pp. 438 - 441, 1995) and an anti-Fas antagonist antibody (Alderson M.A. *et al.*, *Int. Immunol.*, vol. 6, pp. 1799 - 1806, 1994).

[0016] Nagata *et al.* have also reported that they succeeded in obtaining an antibody against the Fas ligand, and that such antibody was capable of suppressing the apoptosis (Masato Tanaka, *et al.*, *EMBO Journal*, vol. 14, pp. 1129 - 1135, 1995; International Patent Application Laid-Open No. WO95/13293).

[0017] As described in the foregoing, as Fas antigens have been isolated, it has been revealed that apoptosis is induced via these Fas antigens in the living body and the Fas antigen-mediated apoptosis is concerned in various diseases, so that it is considered that a substance capable of controlling the Fas antigen-mediated apoptosis will be useful in the prevention, treatment and diagnosis of diseases in which apoptosis is presumably concerned. Though usefulness of a pharmaceutical preparation in the living body should be evaluated by synthetically taking its activity, biological behavior, safety, side effects and the like into consideration, a substance having particularly high activity will exert its efficacy at a low dosage in the living body so that it will have high industrial availability. Because of this, great concern has been directed toward the development of an improved novel Fas antigen derivative, especially a Fas antigen derivative having more high activity, and the elucidation of its characteristics, particularly, when its application to the living body such as human treatment is taken into consideration, a novel Fas antigen derivative capable of controlling the Fas antigen-mediated apoptosis at more smaller dosage is expected from the viewpoint of efficacy and safety.

[0018] In addition, acquisition of a novel Fas antigen derivative is also important for the elucidation of, for example, interaction of Fas antigen and Fas ligand and mechanism of the Fas antigen-mediated apoptosis.

[0019] It is known that a polypeptide can show its activity even in the form of its partial fragment when the fragment preserve its intrinsic structure at the active site. On the contrary, however, many cases are also known in that the activity of a polypeptide is changed, or lost in an extreme case, by a mutation or deletion of even one amino acid in the polypep-

tide.

[0020] Thus, an object of the present invention is to provide the field of medicaments with a novel Fas antigen derivative whose activity and the like are improved and with a novel DNA fragment which encodes the same. The present invention also provides a recombinant DNA molecule and a transformant, which contains said DNA fragment, and a method for the production of said novel Fas antigen derivative.

#### DISCLOSURE OF THE INVENTION

[0021] Under the aforementioned situation, the inventors of the present invention have found that a novel Fas antigen derivative in which specified numbers of amino acid residues are deleted from the N-terminal region of Fas antigen shows improved activity or function in comparison with the prior art Fas antigen or Fas antigen derivative, and the present invention has been accomplished as a result of intensive efforts.

[0022] Thus, according to a first aspect of the present invention, there is provided a novel Fas antigen derivative, at least a novel Fas antigen derivative which comprises at least a part or entire portion of Fas antigen extracellular region polypeptide in which at least one amino acid residue is deleted from a group of amino acid residues starting from the N-terminal amino acid residue of the Fas antigen polypeptide to a cysteine residue most close to the N-terminal side (excluding said cysteine residue). It also provides a novel Fas antigen derivative according to the above wherein it contains a part or entire portion of Fas antigen extracellular region polypeptide in which at least one amino acid residue is deleted from the 1st to 42nd amino acid residues counting from the N-terminus of the Sequence ID No. 15 in the Sequence Listing, and a novel Fas antigen derivative according to the above wherein the number of deleted amino acid residues is 29 or more, particularly a novel Fas antigen derivative according to the above wherein the number of deleted amino acid residues is 29.

[0023] It also provides a novel Fas antigen derivative which is a novel Fas antigen variant of the aforementioned derivative wherein it comprises 1 or 2 or more parts of Fas antigen or is a fusion polypeptide that comprises either one of the novel Fas antigen variants and other (poly)peptide, particularly at least one (poly)peptide selected from the group consisting of the following peptides, which is contained in the C-terminal side of the novel Fas antigen derivative.

- a. A part or entire portion of the hinge region of immunoglobulin.
- b. A part or entire portion of the Fc fragment of immunoglobulin.

[0024] It also provides a novel Fas antigen derivative which is a polymer of the aforementioned novel Fas antigen derivative.

[0025] According to a second aspect of the present invention, there is provided a DNA fragment which comprises a DNA sequence coding for the aforementioned novel Fas antigen derivative, particularly a DNA fragment which comprises the DNA sequence described in the Sequence ID Nos. 12 to 14 of the Sequence Listing.

[0026] According to a third aspect of the present invention, there is provided a recombinant DNA molecule which comprises the nucleotide sequence of said DNA fragment.

[0027] According to a fourth aspect of the present invention, there is provided a transformant which is transformed with the just described novel recombinant DNA molecule.

[0028] According to a fifth aspect of the present invention, there is provided, among production methods of the aforementioned novel Fas antigen derivative, a method for the production of the aforementioned novel Fas antigen derivative, which comprises the steps of culturing the just described transformant and recovering and purifying the novel Fas antigen derivative from said culture mixture.

[0029] According to a sixth aspect of the present invention, there is provided a medicament which comprises the novel Fas antigen derivative of the first aspect or a physiologically acceptable salt thereof as its active ingredient.

[0030] According to a seventh aspect of the present invention, there is provided a method for the improvement of the activity or function of Fas antigen or Fas antigen derivative, which comprises deleting at least one of the amino acid residues starting from the N-terminal amino acid residue of the Fas antigen to a cysteine residue most close to the N-terminal side (excluding said cysteine residue).

[0031] In this connection, the known human Fas antigen contains an amino acid sequence deduced from the cDNA sequence shown in Figs. 1 and 2 (Sequence ID No. 16). It is assumed that the antigen is present as a type I transmembrane protein composed of 319 amino acids as a result of the cutting of its signal peptide consisting of 16 residues from the amino acid sequence and that it has an extracellular region of 157 amino acids (from 1st to 157th residues), a transmembrane region of 17 amino acids (from 158th to 174th residues) and a cytoplasmic tail region of 145 amino acids (from 175th to 319th residues). The extracellular region of human Fas antigen has a function to bind to Fas ligand, and a polypeptide resulting from the expression of the extracellular region alone exists as a soluble type and shows an apoptosis inhibiting activity by binding to the Fas ligand. In addition, according to the computer analysis of the present invention which will be described later in detail, there is a possibility that the 43rd cysteine residue counting from the N-

terminus is forming a certain bonding with other amino acid residue, thereby contributing to the maintenance of the domain structure of Fas antigen extracellular region. On the other hand, the cysteine residue most close to the C-terminus of the Fas antigen extracellular region also seems to be necessary for the structure maintenance, but, since the aforementioned  $\Delta$  TM type Fas antigen binds to the Fas ligand, it is presumed that the 5 residues in the C-terminus, namely from the 153rd glycine residue to the 157th asparagine residue, are not necessary for the activity.

## BRIEF DESCRIPTION OF THE DRAWINGS

[0032]

Fig. 1 is a chart showing nucleotide sequence of a DNA fragment coding for human Fas antigen and amino acid sequence deduced therefrom. The symbol \* shows possible N-glycosylation site, and the underlined part shows predicted transmembrane region.

Fig. 2 is a chart showing nucleotide sequence of a DNA fragment coding for human Fas antigen and amino acid sequence deduced therefrom. The symbol \* shows possible N-glycosylation site, and the underlined part shows predicted transmembrane region.

Fig. 3 is a chart showing partial nucleotide sequence in a vector containing a cDNA nucleotide sequence (Sequence ID No. 17) coding for shFas(nd29) which is one of the novel Fas antigen derivatives of the first aspect of the present invention, and amino acid sequence deduced therefrom. The symbol \* shows possible N-glycosylation site.

Fig. 4 is a chart showing partial nucleotide sequence in a vector containing a cDNA nucleotide sequence (Sequence ID No. 18) coding for shFas(nd29)-Fc which is one of the novel Fas antigen derivatives of the first aspect of the present invention, and amino acid sequence deduced therefrom. The symbol \* shows possible N-glycosylation site.

Fig. 5 is a chart showing partial nucleotide sequence in a vector containing a cDNA nucleotide sequence (Sequence ID No. 19) coding for shFas(nd29)-hinge which is one of the novel Fas antigen derivatives of the first aspect of the present invention, and amino acid sequence deduced therefrom. The symbol \* shows possible N-glycosylation site.

Fig. 6 is a photograph showing results of gel electrophoresis of shFas(nd29)-Fc and hFas-Fc.

Fig. 7 is a photograph showing results of gel electrophoresis of shFas(nd29)-hinge before gel filtration chromatography.

Fig. 8 is a photograph showing results of gel electrophoresis of shFas(nd29)-hinge after gel filtration chromatography.

Fig. 9 is a graph showing cell apoptosis inhibiting activity of hFas-Fc and shFas(nd29)-Fc.

Fig. 10 is a graph showing cell apoptosis inhibiting activity of hFas-Fc and shFas(nd29)-Fc.

Fig. 11 is a graph showing cell apoptosis inhibiting activity of hFas-Fc and shFas(nd29)-hinge.

Fig. 12 is a graph showing cell apoptosis inhibiting activity of hFas-Fc and shFas(nd29)-hinge.

Fig. 13 (a) to (d) are graphs showing activities of hFas-Fc and shFas(nd29)-Fc to inhibit increment of GOT and GPT.

Fig. 14 (a) to (d) are graphs showing actions of hFas-Fc and shFas(nd29)-hinge to inhibit increment of GOT and GPT.

Fig. 15 (a) to (c) are schematic illustrations showing comparison of amino acid sequences of human Fas antigen, human Fas antigen extracellular region (shFas), hFas-Fc, shFas(nd29)-Fc and shFas(nd29)-hinge.

## BEST MODE OF CARRYING OUT THE INVENTION

[0033] The following describes the present invention in detail.

[0034] In the description of the novel Fas antigen derivative of the present invention, the term "a novel polypeptide containing an amino acid sequence (or (poly)peptide or the like)" has the following meaning. It means firstly that the novel polypeptide may be defined by its amino acid sequence, secondly that at least one optional amino acid may be added to either one or both of the N-terminus and C-terminus of the amino acid sequence and that, when the novel polypeptide is a fusion polypeptide or a polypeptide containing two or more functional regions, at least one optional amino acid may be added to (inserted into) their fused point or a site between the functional regions.

[0035] Also, the term "a polypeptide containing at least a part of an amino acid sequence (or (poly)peptide or the like)" means a novel polypeptide which contains entire portion of the amino acid sequence or a polypeptide that contains an optional partial sequence having an optional length of the amino acid sequence.

[0036] Also, in the description of the novel Fas antigen derivative of the present invention, the term "Fas antigen derivative" or "Fas antigen derivative polypeptide" means a polypeptide which contains at least a part of Fas antigen, and its examples include Fas antigen variants, a fusion polypeptide of Fas antigen or a Fas antigen variant with other

(poly)peptide, and polymers thereof, as well as those which contain compounds other than the (poly)peptide.

[0037] The term "Fas antigen variant" or "Fas antigen variant polypeptide" as used herein means a polypeptide which comprises a part or two or more parts of Fas antigen, does not basically contain a (poly)peptide of other origin than Fas antigen and has at least one of the activities and functions of Fas antigen, and its examples include truncated Fas antigens and variants of Fas antigen in which one or more amino acids are deleted or substituted (to be referred to as deletion product or substitution product hereinafter in some cases), such as Fas antigens in which extracellular region, transmembrane region (like  $\Delta$ TM type Fas antigen (Fas  $\Delta$ TM)), or cytoplasmic tail region is deleted, and the like.

[0038] The term "fusion protein" as used herein means a polypeptide in which two or more (poly)peptides in a combination which does not exist naturally are linked to one another directly or indirectly, preferably directly, by chemical bonding, preferably peptide bonding.

[0039] The term "N-terminal region" of Fas antigen as used herein, in the case of the human Fas antigen (Figs. 1 and 2) for example, may include amino acid residues of the signal peptide (from -16 position Met to -1 position Ala in Fig. 1) in a broad sense, but, in the case of the novel Fas antigen derivative of the present invention, an N-terminal amino acid residue (Arg) resulting from the truncation of the signal peptide from the Fas antigen is used as the N-terminus, so that the term means a region starting from the N-terminal amino acid residue (Arg) and ending by an amino acid residue (42 position Phe) just before the first cysteine residue (43 position).

[0040] Examples of the term "activity or function" as used herein include Fas ligand binding activity, biological activities such as apoptosis inhibiting activity, apoptosis inducing activity and the like which will be described later and functions resulting from stability, biological behavior, solubility and the like physico-chemical properties, of which Fas ligand binding activity and actions upon apoptosis are desirable and apoptosis inhibiting activity is particularly desirable.

[0041] In addition, the term "has an improved activity or function" as used herein means that at least one of the activity and the like values is at least larger, for example 1.4 times or more, preferably 2 times or more, more preferably 3 times or more, most preferably 5 times or more and most particularly preferably 10 times or more, than that of a polypeptide from which the corresponding N-terminal region is not deleted (N-terminal region non-deleted product). The activity values and the like can be measured by generally used methods and compared as their activity quantities per unit quantity, namely specific activities. The specific activity is generally calculated as 50% inhibition concentration ( $IC_{50}$ ) or 50% effective dose ( $ED_{50}$ ).

[0042] The novel Fas antigen derivative of the first aspect of the present invention is at least a novel Fas antigen derivative which at least comprises a part or entire portion of Fas antigen extracellular region polypeptide in which at least one amino acid residue is deleted from a group of amino acid residues starting from the N-terminal amino acid residue of the Fas antigen polypeptide to a cysteine residue most close to the N-terminal side (excluding said cysteine residue). In this connection, the just described part or entire portion of Fas antigen extracellular region polypeptide in which at least one amino acid residue is deleted and the novel Fas antigen derivative of the present invention are possessed of at least a function to bind to a Fas ligand.

[0043] Origin of the Fas antigen from which one or more amino acid residues are to be deleted is not particularly limited, but a mammal Fas antigen, particularly a human antigen such as an antigen which contains the known amino acid sequence of the human Fas antigen shown in Figs. 1 and 2 is desirable.

[0044] When the Fas antigen from which one or more amino acid residues are to be deleted is the human Fas antigen shown in Figs. 1 and 2, the novel Fas antigen derivative of the present invention is a novel Fas antigen derivative in which at least one amino acid residue is deleted from the 1st to 42nd amino acid residues counting from the N-terminus of the Sequence ID No. 15 (human Fas antigen extracellular region) in the Sequence Listing, preferably a novel Fas antigen derivative in which the number of deleted amino acid residues is 29 or more, more preferably 29.

[0045] The amino acids to be deleted may be continued or discontinued on the amino acid sequence but preferably continued, and, in that case, it is desirable to delete them preferentially from the N-terminal side. That is, a novel Fas antigen derivative in which 29 amino acid residues of from the 1st to 29th positions counting from the N-terminus of the Sequence ID No. 15 of the Sequence Listing are deleted, so that it starts from the 30th Thr residue, is particularly desirable.

[0046] Also, with regard to the number and position of N-terminal region amino acid residues desirable to be deleted, results of the three-dimensional structure analysis of Fas antigen extracellular region and the like by a computer can be used, which will be described in detail in Examples. That is, it is possible to optimize or control affinity and the like with a Fas ligand by designing the Fas antigen in the three-dimensional structure analysis in such a manner that the N-terminal region structure of the antigen does not cause steric hindrance for its binding with the Fas ligand.

[0047] In addition, there is a possibility that the N-terminal region of Fas antigen is apt to receive hydrolysis by protease and the like because of its structural characteristics. Also, since there is a possibility that processing of the polypeptide differs qualitatively or quantitatively depending on the host, these points and solubility, stability and the like can be taken into consideration when the N-terminal region is deleted.

[0048] When the above points are taken into consideration, the number of amino acid residues desirable to be deleted from the N-terminal region is preferably 13 to 18 or more, more preferably 23 or more, most preferably 29 or more, in



the case of the human Fas antigen, and, in any case, it is desirable not to delete 36th to 42nd amino acid residues counting from the N-terminus.

[0049] With regard to the N-terminal region amino acid residues, particularly in the case of human Fas antigen, the novel Fas antigen derivative of the present invention includes a novel Fas antigen derivative which is a novel Fas antigen variant that comprises a part or entire portion of the Fas antigen extracellular region in which at least one amino acid residue is deleted from the 1st to 42nd amino acid residues counting from the N-terminus of the Sequence ID No. 15 in the Sequence Listing, particularly a novel Fas antigen variant which comprises 1 or 2 or more parts of the Fas antigen in which the number of deleted amino acid residues is preferably 29 or more, more preferably 29.

[0050] Illustrative examples of the Fas antigen variant of the present invention include those which contain a polypeptide of 158th to 174th residues, a polypeptide of 175th to 319th residues and a polypeptide of 158th to 319th residues, as well as a variant in which optional fragments having optional lengths obtained from the polypeptide of 158th to 319th residues are combined in optional order and included in the C-terminal or N-terminal side, preferably the C-terminal side, of the Fas antigen variant.

[0051] In this connection, the novel Fas antigen variant in which the number of deleted amino acid residues is 29 is preferably a variant that contains the amino acid sequence of Sequence ID No. 9 (shFas(nd29)) of the Sequence Listing, more preferably a variant which comprises said amino acid sequence.

[0052] Combined products with other chemical substances such as (poly)peptides, sugar chains, lipids or other high molecular weight or low molecular weight compounds and the like are included in the novel Fas antigen derivative, of which a fusion polypeptide with other (poly)peptide is desirable. Said (poly)peptide is not particularly restricted and two or more (poly)peptides may be included, and, in the latter case, binding order of said two or more (poly)peptides can be changed and substances other than amino acids may be included.

[0053] The bonding type of other chemical substances and the like with the essential novel Fas antigen variant is not particularly limited, and the bonding may be effected by any of covalent bonds and non-covalent bonds, but preferably by a covalent bond in view of the bonding stability. Particularly, peptide bond is desirable when the other chemical substance is a (poly)peptide.

[0054] The binding site can also be selected at will and any of the N-terminus, C-terminus and side chains can be used as the binding site, but the bonding may be effected mediated preferably by either one or both of the termini, more preferably by the C-terminus.

[0055] Then the other chemical substance is a (poly)peptide, it is desirable that said (poly)peptide is a (poly)peptide which has an action to improve or modify activity or function of said novel Fas antigen derivative. For example, those which improve stability or half-life in blood or increase accumulation into specified tissues, cells or other specific regions are included, and Fc fragment can be cited as an example which can prolong blood half-life. Particularly preferred is a (poly)peptide which has such a function that said novel Fas antigen derivative becomes a polymer. Examples of the polymerizable (poly)peptide include entire portion or a part of the constant region of immunoglobulin heavy chain or light chain, entire portion or a part of the heavy chain constant region excluding its first region (CH1) and entire portion of the Fc fragment (it may comprise hinge region, CH2 region and CH3 region in the case of IgG) or a part thereof (for example, each of or an optional combination of hinge region, CH2 region, CH3 region and CH4 region), of which a portion that comprises the Fc fragment and at least a part of the hinge region is desirable, a portion of the hinge region which contains at least one, preferably all, of cysteine residues of the hinge region, or a Fc fragment containing said hinge region portion or CH3 region (CH4 region in the case of IgM and IgE) or a portion of hinge region is more desirable, and entire portion or a part of the Fc fragment containing the whole hinge region or the hinge region itself is most desirable.

[0056] The immunoglobulin of this case may be of any origin but preferably of human origin. Also, its class and subclass are not necessarily restricted, and any one of IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, IgM, IgE and IgD and the like can be used, of which IgG is a preferred example. The novel Fas antigen derivative containing Fc fragment and the like can generally form a dimer, but it may also form a decamer when the original class is IgM or a tetramer in the case of IgA.

[0057] By the way, it is known that constant region, particularly Fc region, of immunoglobulin is important for various effector functions and the like of the antibody molecule, which are not directly concerned in the antigen specificity of the antibody. Examples of such functions include binding and activation of complements, binding with Fc receptors (FcR), induction of ADCC activity, placenta passing ability, degranulation of mast cells and protein A reactivity.

[0058] Though these functions can be utilized effectively when incorporated into the novel Fas antigen derivative of the present invention, they have a possibility to cause induction of side effects when administered to the living body as a medicament in certain cases, for example in a specific disease. In that case, therefore, an Fc fragment or the like from which all or a part of these effector functions and the like are removed is desirable, and its preferred examples include an Fc variant in which a mutation is introduced into the sugar addition site of the CH2 region of IgG, thereby deleting the sugar chain of said site, constant region or Fc fragment of IgG from which the CH2 region is deleted and hinge region.

[0059] In the novel Fas antigen derivative, binding of the novel Fas antigen variant with other (poly)peptide and the like may preferably be effected directly, but indirectly in some cases such as their bonding via a peptide linker or an appropriate chemical spacer which does not significantly spoil activities and functions of the novel Fas antigen derivative.

5 [0060] Activities and functions of the novel Fas antigen derivative of the present invention are further improved by its polymerization.

[0061] The polymer includes all of its dimer and more larger ones, but preferably dimer to decamer, more preferably dimer or trimer, most preferably dimer. It includes homo- and heteropolymers, but a homopolymer is more desirable.

10 [0062] With regard to the polymerization method, it is desirable to use polymerizing property of a (poly)peptide which by itself is polymerizable. A method in which the aforementioned polymerizing property of the constant region of immunoglobulin or its parts (Fc fragment and hinge region for example) is used is particularly desirable, but a cysteine-containing peptide which can form a hinge-like structure or a polypeptide which contains said peptide may also be used. In addition to the above, the cytoplasmic tail region of Fas antigen, TNF-R or the like may also be used. Though bonding of monomers in the polymer may be effected by any bond, a covalent bond (disulfide bond or peptide bond for example)

15 is desirable, while a non-covalent bond (for example, bonding between two CH<sub>3</sub> regions of immunoglobulin or between cytoplasmic tail regions of Fas antigen or TNF-R) can also be used.

[0063] In addition to the above, the following methods by chemical cross-linking can be employed. For example,

20 1) cysteine is introduced into the C-terminus and then cross-linking is effected using two types of activation linkers.

There is a method for the introduction of cysteine in which cysteine amide or carboxypeptidase Y is used. Then the C-terminus is lysine, lysine endopeptidase is used. Also, when free cysteine is present, protection is carried out in advance by alkylation prior to the introduction of cysteine into the C-terminus. Thereafter, cross-linking is carried out using activation linkers. For example, N,N'-o-phenylene dimaleimide (Glennie, M.J. *et al.*, *J. Immunol.*, vol. 139, pp. 2367 - 2375, 1987) or the like as a divalent cross-linking agent and a tris-maleimide compound (Japanese Patent Application Kokai No. 6-228091) or the like as a trivalent cross-linking agent have been used in the cross-linking of antibodies and can be applied to the novel Fas antigen derivative of the present invention to form a dimer and a trimer, respectively.

25 2) Biotin is introduced into the C-terminus and then cross-linking is carried out using avidin. It is introduced into the C-terminus using biotin amide similar to the case of cysteine. A tetramer is formed by the avidin cross-linking, but more higher aggregate may be formed depending on the reaction conditions. Also, other functional polypeptide or the like can be bound. The bond between biotin and avidin is an example of the strong non-covalent bonds.

30 3) Cross-linking is carried out using a cross-linking agent which is specific to cysteine, thiol or amino group present in the sequence of the novel Fas antigen derivative or (poly)peptide or the like linked to the derivative.

35 [0064] In the above cases, a peptide or chemical linker or a spacer having an appropriate length can be used.

[0065] Also, it is possible to make the novel Fas antigen derivative into liposomes by including lipid, hydrophobic peptide or the like fat-soluble substance according to known methods. For example, the novel Fas antigen derivative of the present invention which contains the transmembrane region of Fas antigen can be incorporated by itself into liposomes and the like. These liposomes are high degree polymers, and their appropriate modifications render possible further applications such as their incorporation into certain cells and tissues.

40 [0066] Among novel Fas antigen derivatives of the present invention, preferred examples having polymerization ability include those which contain the amino acid sequences of the Sequence ID Nos. 10 (shFas(nd29)-hinge) and 11 (shFas(nd29)-Fc) of the Sequence Listing, more preferably a derivative composed of said sequences.

[0067] Among the polymers of the polypeptides of the Sequence ID Nos. 10 and 11, the dimer is a dimerization product of the Fas antigen derivative of the present invention in which its activities are improved by deleting 29 amino acid residues from the N-terminus of the extracellular region of human Fas antigen, and the improved activities are not spoiled by the dimerization so that the resulting dimer is possessed of markedly high Fas ligand binding activity and apoptosis-inhibiting activity.

50 [0068] In general, a polypeptide in different species or individuals generates different amino acid sequences caused by mutation during the process of its evolution while basically preserving original functions of the peptide. The term mutation of amino acid sequence as used herein means 1) deletion of one or more amino acid residues in the amino acid sequence of the polypeptide, 2) substitution by other amino acid residues or 3) insertion or addition of one or more amino acid residues into or to optional sites of the aforementioned amino acid sequence. Such mutations can be artificially generated using genetic engineering techniques, and polypeptides having such mutations are also included in the novel Fas antigen derivative of the present invention.

55 [0069] In addition, the novel Fas antigen derivative may have a methionine residue or one or more amino acid residues originated from a signal peptide or propeptide, added to the N-terminus.

[0070] The novel Fas antigen derivative of the first aspect of the present invention may have any modification with the

proviso that its characteristics are not spoiled. Examples of the modification include modifications during or after translation of the polypeptide, which will usually occur in natural protein, and chemical modifications. Addition of sugar chain and the like can be cited as examples of the natural modification, N-glycosylation, O-glycosylation, non-enzymatic sugar addition and the like are known as the sugar addition to protein, and the novel Fas antigen derivative of the first aspect of the present invention may or may not have any sugar chain.

[0071] The novel Fas antigen derivative of the present invention may have N-glycosylation site(s), such as the case of the 29 N-terminal amino acid residues-deleted Fas antigen extracellular region which has two N-glycosylation sites. In consequence, said novel Fas antigen derivative may have sugar chains depending on the host which produces the derivative. That is, it is considered that the just described protein may have sugar chains on the aforementioned N-glycosylation sites when produced by using eucaryotic cells such as animal cells or yeast as the host cells, but may not have sugar chains when procaryotic cells such as *Escherichia coli* are used as the host. In addition, the number and length of the sugar chain or sugar composition and sequence of the sugar chain are not particularly limited, because they vary depending on the medium composition and the like at the time of the culturing of these host cells. Other examples of the natural modification include bonding of lipid and the like.

[0072] With the technical development in recent years, it became possible to modify polypeptide in various ways. Examples of the possible modification site include amino acid residues of the N-terminus or C-terminus and functional groups of the side chains. For example, it became possible to combine a polypeptide with polyethylene glycol, styrene-maleic acid copolymer, dextran, pyran copolymer, polylysine and the like synthetic high polymers, lipids, polysaccharides, (poly)peptides and the like natural molecules, hormones and the like physiologically active molecules or magnetite and the like inorganic substances (*Proc. Natl. Acad. Sci. USA*, vol. 84, pp. 1487 - 1491, (1981); *Biochemistry*, vol. 28, pp. 6619 - 6624 (1989)).

[0073] Examples of other modified derivatives include N-acyl derivatives of free amino group of an amino acid residue formed by the amido or acyl residue of carboxyl group resulting from the reaction of an aliphatic ester of carboxyl group with ammonia or a primary or secondary amine (an alkanoyl or carboxylaroyl group for example) and O-acyl derivatives of free hydroxyl group formed by an acyl residue (for example, hydroxyl group of serine or threonine residue).

[0074] The novel Fas antigen derivative of the present invention can also be modified in the aforementioned manner by the combination of the aforementioned known techniques. In consequence, products of such modifications are also included in the novel Fas antigen derivative of the present invention, with the proviso that characteristics of the polypeptide of the first aspect of the present invention are not spoiled. In addition, it is possible to modify or improve the activity or function of the novel Fas antigen derivative of the first aspect of the present invention, or to add or combine other activity or function, by such modifications. Examples of such activity or function include stability, solubility, biological behavior and directivity toward specified cells, tissues or organs. The novel Fas antigen derivatives which received such modifications are also included in the present invention.

[0075] The novel Fas antigen derivative of the present invention may exist in the form of salts which are also included in the present invention. The term "salts" as used herein means both of the salts of carboxyl groups of the protein molecule and acid addition salts to amino groups. The salts of carboxyl groups can be formed by the methods well-known in the field of these techniques, and their examples include inorganic salts such as salts of sodium, calcium, ammonium, trivalent iron, zinc and the like and organic salts such as those which are formed by triethanolamine, arginine, lysine, piperidine, procaine and the like. Examples of the acid addition salts include salts with hydrochloric acid, sulfuric acid and the like mineral acids and salts with acetic acid, oxalic acid and the like organic acids.

[0076] The novel Fas antigen derivative of the present invention can be applied to medicaments and, in that case, it is desirable that the aforementioned modification and the like techniques can keep pharmaceutical acceptability.

[0077] In addition, method for the production of the aforementioned novel Fas antigen derivative of the first aspect is not particularly limited, so that it may be isolated and purified from a natural source, artificially synthesized using a usually used chemical synthesizer (Peptide Synthesizer Model 430A, Perkin-Elmer Japan) or obtained by the recombinant DNA techniques. Also, the thus isolated and purified peptide may be subjected to an appropriate chemical treatment, such as an enzymatic treatment, to obtain deletion or fragmentation products which may further be linked together chemically or polymerized. That is, monomers of the novel Fas antigen derivative of the present invention are also useful as intermediates or intermediate materials for the production of polymers.

[0078] Among the aforementioned derivatives, a peptide produced by means of genetic engineering techniques, which will be described later as the fifth aspect of the present invention, is desirable from the viewpoint of the productivity and homogeneity or purity of the produced protein, such as its nature of being free from other contaminated human proteins.

[0079] An example of the production by genetic engineering techniques is briefly described in the following. The plasmid pM1097 which will be described later in Inventive Example 1 (1) contains a DNA fragment represented by the nucleotide sequence of the Sequence ID No. 12 which encodes the amino acid sequence of the Sequence ID No. 9 shown in the Sequence Listing and another DNA fragment that encodes the signal peptide of Fas antigen. Using an appropriate vector such as an expression vector shown in Examples constructed by integrating the just described plas-

mid into plasmid pM1103 prepared by integrating *dhfr* gene into pEF-BOS, COS-1 cells were transformed to obtain a transformant and then shFas(nd29) was obtained from its culture supernatant.

[0080] Among activities and functions of the novel Fas antigen derivative of the present invention, the apoptosis inhibiting activity can be examined by measuring inhibition ratio of Fas antigen expression cells to apoptosis. For example, it is measured by the <sup>51</sup>Cr release assay or MTT assay (Mosmann T., *J. Immunol. Methods*, vol. 65, pp. 55 - 63, 1983) using a cultured cell strain or transformed cells capable of expressing Fas antigen as the target Fas antigen expression cells, and Fas ligand expressing cells obtained by transformation or a soluble type Fas ligand such as the Fas ligand extracellular region as the effector. Illustrative methods are shown in Examples. Apoptosis inhibiting activity of said novel Fas antigen derivative on WC 8 cells obtained by transforming mouse WR19L cells to give Fas antigen expressing ability is at least larger, for example 1.4 times or more, preferably 2 times or more, more preferably 3 times or more, most preferably 5 times or more and most particularly 10 times or more, than that of its corresponding N-terminal region non-deleted Fas antigen (derivative).

[0081] Since the novel Fas antigen derivative of the present invention can control Fas antigen-mediated apoptosis, it is useful for the prevention and treatment of diseases related to the sthenia or failure of Fas antigen-mediated apoptosis induced in the living body. For example, since a preferred novel Fas antigen derivative of the present invention can inhibit induction of apoptosis by competitively inhibiting bonding between Fas ligand and Fas antigen, it is possible to prevent reduction of functions of tissues and organs by inhibiting apoptosis of hepatic cells and the like in the case of hepatitis and the like serious infectious diseases and thereby preventing rapid reduction of cells in major organs and tissues, and it can be used for the treatment of infectious diseases caused by viruses and the like and complications thereof, for example as a drug for use in the treatment of influenza, AIDS, hepatitis and the like diseases. It is also useful for the treatment of certain autoimmune diseases such as diabetes, myocardiopathy in reperfusion injury and the like ischemic heart diseases, nephritis, multiple organ failure and organ preservation and graft versus host disease (GVHD) at the time of organ transplantation.

[0082] Since the novel Fas antigen derivative of the present invention binds to Fas ligand with more specific and high affinity, it can be used for the detection of Fas ligand. Also, since it keeps at least a part of the antigenicity of Fas antigen, it can bind to anti-Fas antibody and therefore is effective in inhibiting apoptosis caused by the anti-Fas antibody.

[0083] In addition, when Fas ligand itself is used in treatments and studies, it is necessary to produce said protein in a large amount with a high purity, and, since the novel Fas antigen derivative of the present invention can be used for the preparation of affinity chromatography columns, it is also useful in purifying Fas ligand and the like substances which bind to Fas antigen.

[0084] The second aspect of the present invention is a DNA fragment which encodes the novel Fas antigen derivative of the first aspect of the present invention.

[0085] In the description of the DNA fragments and DNA molecules in this specification, the term "a DNA fragment containing a nucleotide sequence" means that the DNA fragment may be a DNA fragment which comprises the nucleotide sequence or a fragment that comprises a variant of the nucleotide sequence in which at least one optional base is added to either one or both of its 5'-end and 3'-end.

[0086] The novel DNA fragments of the present invention contains at least a part of a nucleotide sequence which encodes the novel Fas antigen derivative of the first aspect of the present invention, preferably the amino acid sequences of the Sequence ID Nos. 9 to 11 of the Sequence Listing. Since it is generally known that there are 1 to 6 different DNA triplets (codons) which encode an amino acid depending on each amino acid, the DNA nucleotide sequences which encodes amino acid sequence of the novel Fas antigen derivative of the first aspect of the present invention are not limited to one type. In consequence, all DNA fragments comprised of every nucleotide sequence are included in the present invention, provided that they are DNA fragments which contain at least a part, preferably entire portion, of a nucleotide sequence which encodes the novel Fas antigen derivative of the first aspect of the present invention, preferably the amino acid sequences of the Sequence ID Nos. 9 to 11 of the Sequence Listing. The novel DNA fragment of the present invention is more preferably a DNA fragment which contains at least a part of the Sequence ID Nos. 12 to 14 of the Sequence Listing among the nucleotide sequences coding for the amino acid sequences of the Sequence ID Nos. 9 to 11 of the Sequence Listing, most preferably which contains all of the nucleotide sequences of the Sequence ID Nos. 12 to 14 of the Sequence Listing.

[0087] The DNA fragment of the present invention may be a cDNA molecule, a chromosomal DNA fragment, a combination thereof or a cDNA molecule which contains introns that can suitably be spliced. However, it is desirable that the DNA fragment of the present invention is a cDNA molecule because of its easiness to handle for genetic engineering techniques.

[0088] According to the present invention, it also provides an RNA molecule corresponding to the novel DNA fragment of the present invention and a DNA fragment containing a sequence complementary to the novel DNA fragment of the present invention and its corresponding RNA molecule. The novel DNA fragment of the present invention and its complementary DNA and RNA may form a double-stranded or triple-stranded chain through their mutual complementary bonding. Also provided are a DNA fragment which contains a nucleotide sequence capable of hybridizing with the novel

DNA fragment of the present invention and its corresponding RNA molecule. In this case, they may also form a double-stranded or triple-stranded chain through their mutual bonding. In the above case, it may have inosine or the like universal base as a nucleic acid base.

[0089] The DNA fragment of the second aspect of the present invention may be obtained by any method. For example, it may be chemically synthesized, obtained from an appropriate DNA library or obtained by PCR (polymerase chain reaction) method using, as a template, a DNA fragment containing a DNA fragment which encodes whole length or a part of human Fas antigen. Also, the DNA fragments obtained by these methods or their smaller fragments may be further subjected to annealing and ligation as occasion demands.

[0090] The DNA fragment of the present invention can be synthesized chemically in the following manner. Illustratively, the DNA fragment of the present invention is divided into fragments of about 20 to 30 bases and synthesized as a plurality of fragments using a DNA synthesizer (for example, Model 394, manufactured by Applied Biosystems) and then each of the fragments is subjected to the phosphorylation of its 5'-end as occasion demands and then to annealing and ligation, thereby obtaining the DNA fragment of interest.

[0091] The DNA fragment of the present invention can also be obtained by PCR method using a genomic library, cDNA library or the like as the template. When PCR method is used, it can be obtained by preparing sense and anti-sense primers designed based on known nucleotide sequences and the nucleotide sequence of a DNA fragment which encodes the novel Fas antigen derivative of the first aspect of the present invention in combination, if necessary, with a restriction enzyme recognition sequence and the like, and then carrying out the reaction in accordance with the known method (cf. Polymerase Chain Reaction, PCR Protocols, a guide to methods and applications (1990), edited by Michael A.I. *et al.*, published by Academic Press) on an optional DNA library or the like. Its typical example will be described in Examples.

[0092] The aforementioned DNA library is not particularly limited, with the proviso that it contains the DNA fragment of the second aspect of the present invention or a part thereof. In consequence, a commercially available DNA library may be used, or a cDNA library may be prepared in accordance with the method of Sambrook J. *et al.* from human peripheral blood lymphocytes, established human cell line, hybridoma and the like appropriate cells, if necessary activating them with an appropriate activating agent. In this connection, a transformant containing a DNA fragment coding for human Fas antigen has been deposited by the applicant of the present invention in National Institute of Bioscience and Human Technology, Agency of Industrial Science and Technology, the Ministry of International Trade and Industry, Higashi-1-1-3, Tsukuba-shi, Ibaraki, Japan (to be referred to as National Institute of Bioscience and Human Technology hereinafter) and has been assigned the designation as FERM BP-3826.

[0093] The novel DNA fragment of the second aspect of the present invention can be used in the preparation of the recombinant DNA molecule of the third aspect of the present invention and, by transforming a host with the recombinant DNA molecule, can be used for the humogenous and large scale production of the novel Fas antigen derivative of the first aspect of the present invention.

[0094] Because of this, it becomes possible to provide the field of medicaments with the novel Fas antigen derivative as a principal component of therapeutic drugs and diagnostic drugs. Method for the production of the novel Fas antigen derivative of the first aspect of the present invention making use of the novel DNA fragment of the present invention will be described later in relation to the fifth aspect of the present invention.

[0095] In addition, the DNA fragment of the second aspect of the present invention can be applied to the gene therapy of patients having hereditary or acquired abnormality in apoptosis mediated by Fas ligand or Fas antigen. That is, therapeutic and preventive treatments of patients suffering from articular rheumatism, SLE and the like autoimmune diseases and AIDS, hepatitis, nephritis and the like diseases can be carried out by connecting the novel DNA fragment of the present invention to an appropriate vector and introducing it directly into the living body or cells.

[0096] Next, the recombinant DNA molecule of the third aspect of the present invention is described. The recombinant DNA molecule of the third aspect of the present invention is characterized in that it contains the aforementioned novel DNA fragment of the second aspect of the present invention.

[0097] The novel recombinant DNA molecule of the present invention may be in any form such as cyclic, linear, single-stranded, double-stranded or a complex chain thereof, which can be selected at will depending on each purpose, but a cyclic form is desirable in view of easy handling and easy integration into host cells and a double-stranded form is desirable from the stability and the like point of view.

[0098] The novel recombinant DNA molecule of the present invention may be a molecule in which one or more optional bases are added to either one or both of the 5'-end and 3'-end of the nucleotide sequence of the DNA fragment of the second aspect of the present invention.

[0099] The bases to be added are not particularly limited, provided that they do not cause shifting of coding frame in the novel DNA fragment of the present invention, and their examples include an adapter sequence, a linker sequence or a nucleotide sequence which encodes a signal sequence, a nucleotide sequence which encodes  $\beta$ -galactosidase or the like other polypeptide and a sequence which is added when a DNA probe or the like is prepared, for the purpose of increasing its detection sensitivity.

[0100] It is desirable that the recombinant DNA molecule of the present invention contains other nucleotide sequences as occasion demands, in addition to the novel DNA fragment of the second aspect of the present invention. The term "other nucleotide sequences" as used herein means for example an enhancer sequence, a promoter sequence, a ribosome binding site sequence, a nucleotide sequence which is used with the aim of amplifying DNA copy numbers, a translation initiation codon, a nucleotide sequence which encodes a signal peptide, a nucleotide sequence which encodes other polypeptide, a translation termination codon, a poly(A) addition sequence, a spliced sequence, a replication origin and a gene sequence to be used as a selection marker.

[0101] Though selection of necessary nucleotide sequences is decided based on the use of the recombinant DNA molecule to be prepared, they are preferably those which can transform host cells to give them the ability to produce the novel Fas antigen derivative of the first aspect of the present invention, so that said recombinant DNA molecule may preferably contain at least a translation initiation codon, a termination codon, a replication origin and a sequence of a selection marker gene, in addition to the novel DNA fragment of the second aspect of the present invention, and it may contain more preferably a promoter sequence which functions in the host cells. Particularly, it is desirable to add a sequence which encodes a signal peptide in addition to these sequences, because such a sequence renders possible transformation of host cells such that the novel Fas antigen derivative of the first aspect of the present invention can be expressed and secreted. For example, when a recombinant DNA molecule is prepared by connecting a DNA fragment containing entire portions of the nucleotide sequences of the Sequence ID Nos. 12 to 14 of Sequence Listing in an appropriate vector to the downstream of a signal sequence coding for a signal peptide, and an appropriate host is transformed with the thus prepared molecule, culturing of the resulting transformant renders possible secretion of a polypeptide containing the amino acid sequences described in the Sequence ID Nos. 9 to 11 of Sequence Listing into the culture supernatant. Though the signal sequence to be connected can be selected optionally, a signal sequence which encodes the signal peptide of a Fas antigen, particularly human Fas antigen, is desirable, such as a signal sequence which encodes the signal peptide of human Fas antigen shown in Fig. 1 or Fig. 3.

[0102] In addition to the above, other suitable sequences can be used depending on the host and conditions to be employed, by selecting them from sequences which encode for example the signal peptide of TNF or G-CSF, the signal peptide of *E. coli* alkaline phosphatase, the signal peptide of yeast PHO1 and the signal peptide of yeast  $\alpha$ -factor.

[0103] Examples of the selection marker gene include ampicillin resistance gene, kanamycin resistance gene, neomycin resistance gene, thymidine kinase gene and the like, and the novel recombinant DNA molecule containing at least two selection markers is desirable because of the reason that clones transformed with the gene of interest can be selected easily when yeast and mammal cells are used as the host. With regard to the sequence which is used for the purpose of amplifying copy numbers, sequences of dihydrofolate reductase gene (*dhfr*) and the like can be used.

[0104] Examples of the promoter sequence which functions in host cells include sequences of *trp* promoter and *lac* promoter when the host is *E. coli*, and sequences of alcohol oxidase 1 (AOX 1) promoter, polyhedrin promoter, SV40 promoter, SR $\alpha$  promoter and human elongation factor 1 $\alpha$  (EF 1 $\alpha$ ) promoter when the host is yeast, COS cells or the like eucaryotic cells.

[0105] Preferred examples of the recombinant DNA molecule of the present invention, from the viewpoint of the host, include those which can transform *E. coli* cells such that the novel Fas antigen derivative of the first aspect of the present invention can be expressed. In consequence, it is desirable that the recombinant DNA molecule of the present invention is possessed of at least a promoter sequence which functions in *E. coli* cells, in addition to a replication origin and a marker sequence of *E. coli*, more desirably further having a sequence which encodes a signal peptide.

[0106] The *trp* promoter, *lac* promoter or the like is desirable as the suitable promoter sequence which functions in *E. coli* cells, and the signal peptide of *E. coli* alkaline phosphatase is desirable as the signal peptide which functions in *E. coli* cells.

[0107] More preferred example are those which can transform animal cells, yeast and the like eucaryotic cells thereby enabling the cells to express the novel Fas antigen derivative of the first aspect of the present invention. In this case, a suitable example of the recombinant DNA molecule of the present invention may have at least a poly(A) addition sequence in addition to a translation initiation codon, termination codon and a selection marker gene, as well as SV40 promoter, human elongation factor 1 $\alpha$  (EF 1 $\alpha$ ) promoter or SR $\alpha$  promoter which functions in animal cells, alcohol oxidase 1 (AOX 1) promoter which functions in yeast and the SV40 replication origin.

[0108] The recombinant DNA molecule of the third aspect of the present invention can be obtained for example by a method in which the novel DNA fragment of the second aspect of the present invention is allowed to undergo ligation with other DNA fragment having an optional nucleotide sequence or a method in which said fragment is introduced into an optional vector (cf. Sambrook J. *et al.*, Molecular Cloning, a Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory, New York, 1989).

[0109] Illustratively, the DNA fragment and a vector are respectively digested with appropriate restriction enzymes, and the thus obtained fragments are subjected to ligation using a DNA ligase. The vector may be any one of plasmid vectors, phage vectors, virus vectors and the like, and a commercially available article may also be used. Examples of typical vectors include pUC118, pBR322, pSV2-dhfr, pBluescriptII, PHIL-S1,  $\lambda$ ZapII,  $\lambda$ gt10, pAc700, YRP17, pEF-BOS,



pEFN-II and the like, of which pEF-BOS or the like is desirable because of its capability to perform high expression.

[0110] In addition, the recombinant DNA molecule of the third aspect of the present invention may be used in any application. For example, it may be used when the novel Fas antigen derivative of the first aspect of the present invention is produced in an industrial scale or for the purpose of producing the novel DNA fragment of the second aspect of the present invention in a large scale by its amplification. Also, the recombinant DNA molecule of the third aspect of the present invention can be used for the preparation of the transformant of the fourth aspect of the present invention.

[0111] Next, the transformant of the fourth aspect of the present invention is described. The transformant of the present invention is characterized in that it is transformed with the recombinant DNA molecule of the third aspect of the present invention. In other words, the transformant of the present invention can be obtained by introducing the recombinant DNA molecule of the third aspect of the present invention into cells or a microorganisms to be used as the host.

[0112] The transformant of the present invention is obtained by transforming either procaryotic cells or eucaryotic cells. Examples of the procaryotic cells include cells of *E. coli*, *Bacillus subtilis* and the like. Examples of the eucaryotic cells include COS cells, CHO cells, HeLa cells, Namalwa cells and the like mammal cells, as well as Sf cells and the like insect cells and yeast cells. Among these hosts, *E. coli* cells, mammal cells or yeast cells are desirable, because transformants obtained by transforming these cells are easy to handle and high expression quantity can be expected therefrom.

[0113] Since copy number of the gene can be increased in mammal cells, it is desirable to use *dhfr*-defective CHO cells as the host. Also, since the amount of secretion production of exogenous proteins is large in yeast cells, it is desirable to use a yeast of the genus *Pichia* as the host.

[0114] In order to exert functions of the recombinant DNA molecule of the present invention sufficiently, a vector to be used in the preparation of the recombinant DNA molecule of the present invention should be suited for the host cells. Examples of the desirable combination of the vector used in the recombinant DNA molecule with the host include pUC118 with *E. coli*, pEF-BOS with COS cells or CHO cells, Yac with yeast cells and AcNPV with Sf cells (cf. Genetic Engineering Handbook, a special issue of *Experimental Medicine*, published by Yodo-sha, Japan, March 20, 1991). In the same manner, the promoter, a signal peptide encoding nucleotide sequence, marker genes and the like to be contained in the recombinant DNA molecule should be used by selecting those which are suited for the host to be used.

[0115] Also, in order to obtain a transformant capable of expressing the novel Fas antigen derivative of the first aspect of the present invention, said recombinant DNA molecule should have a sequence which is necessary for the expression, such as an appropriate promoter or the like.

[0116] In order to obtain a transformant capable of secreting and producing the novel Fas antigen derivative of the first aspect of the present invention, host cells are transformed with a recombinant DNA molecule which is the aforementioned recombinant DNA molecule of the third aspect of the present invention suited for the production, namely a molecule in which a nucleotide sequence which encodes a signal peptide is included in the upstream of the DNA fragment of the second aspect of the present invention.

[0117] With regard to the method for introducing the recombinant DNA molecule of the third aspect of the present invention into host cells, a method suitable for the host or recombinant DNA molecule may be selected for example from an electroporation method, a protoplast method, an alkali metal method, a calcium phosphate method, a DEAE-dextran method, a microinjection method, a method in which infection is effected using virus particles and other known methods (cf. Genetic Engineering Handbook, a special issue of *Experimental Medicine*, published by Yodo-sha, Japan on March 20, 1991). Since the transformation efficiency of mammal cells becomes high when the calcium phosphate method or DEAE-dextran method is used, it is desirable to use these methods when the host cells are mammal cells.

[0118] The transformant of the present invention is preferably a transformant which can express the novel Fas antigen derivative of the first aspect of the present invention, more preferably which can express said polypeptide and secrete it in the culture supernatant. The use of such a transformant facilitates large scale production of the novel Fas antigen derivative of the present invention.

[0119] Though the transformant of the fourth aspect of the present invention may be used for any purposes, it can be used for the purpose of producing the DNA of the second aspect of the present invention or the recombinant DNA molecule of the third aspect of the present invention in a large amount and of producing the novel Fas antigen derivative of the first aspect of the present invention in an industrial scale.

[0120] The production method of the fifth aspect of the present invention is a method for the production of the novel Fas antigen derivative of the first aspect of the present invention, which is characterized by the use of the transformant of the fourth aspect of the present invention. According to the production method of the present invention, the transformant of the fourth aspect of the present invention is cultured and, if necessary, amplification and expression induction of the gene are carried out. Thereafter, the resulting culture mixture is recovered and then, as occasion demands, purification of the novel Fas antigen derivative of the present invention is carried out by optionally combining concentration, solubilization, dialysis, various chromatographic techniques and the like means.

[0121] In the fifth aspect of the present invention, the term "culture mixture" means a transformant, a medium containing the transformant, culture supernatant or a lysate of the cells. When the produced aforementioned novel Fas anti-

gen derivative is secreted into cell culture supernatant, said polypeptide can be purified from the culture supernatant. On the other hand, when the novel Fas antigen derivative is accumulated in cells of the transformant, the cells are dissolved or disrupted by optionally selecting a method suitable for the host cells from lysozyme treatment, detergent treatment, freeze-thawing, pressurization, ultrasonication and other methods, and then said polypeptide is recovered as a soluble fraction or insoluble fraction and purified.

[0122] When the host is *E. coli* cells and the aforementioned novel polypeptide is accumulated into periplasm, said polypeptide can be recovered by employing the method of Willsky *et al.* (*J. Bacteriol.*, vol. 127, pp. 595 - 609, 1976).

[0123] Culturing of the transformant can be carried out in the usual way with reference to various textbooks (cf. "Methods for Microbial Experiments", edited by Japanese Biochemical Society, published by Tokyo Kagaku Dojin, 1992).

[0124] When expression induction of the gene is carried out, an appropriate agent is selected and used depending on the integrated promoter. For example, 3 $\beta$ -indoleacrylic acid may be used when tip promoter is integrated, dexamethasone may be used in the case of MMTV promoter, and methanol in the case of AOX1 promoter.

[0125] A typical example of the gene amplification method is a method in which *dhfr*-deficient CHO cells are used as the host and methotrexate is used when a *dhfr*-containing vector is used.

[0126] The transformant to be used in said production method is not particularly limited, provided that it is the transformant of the fourth aspect of the present invention, but it is desirably a transformant obtained using a host selected from COS cells, CHO cells and the like mammal cells, yeast cells and *E. coli* cells.

[0127] The following shows examples of the culturing and expression induction when *E. coli*, CRO cell or the like mammal cell or a yeast of the genus *Pichia* is used as the transformant.

[0128] In the case of *E. coli* transformed with a recombinant DNA molecule having *trp* promoter, the cells are pre-cultured in L-broth and then inoculated into M9-CA medium in an inoculum size of 1/50 volume to carry out culturing at 37°C. When the OD550 value reached 1 to 4 (namely the logarithmic growth phase) several hours after commencement of the culturing, 3 $\beta$ -indoleacrylic acid is added to a final concentration of 10  $\mu$ g/ml to carry out expression induction. By further carrying out about 1 to 2 days of culturing, a culture mixture containing the protein of interest can be obtained.

[0129] When a yeast of the genus *Pichia* transformed with a recombinant DNA molecule having AOX1 promoter is used, the yeast is pre-cultured for about 2 days using BMGY medium, the medium is exchanged and then expression induction is effected by adding methanol. By further carrying out about 1 to 2 days of culturing at 30°C, a culture mixture containing the protein of interest can be obtained.

[0130] A transformant obtained by transforming CHO cells or the like mammal cells with a recombinant DNA molecule having the elongation factor promoter is cultured using DMEM medium containing 10% fetal calf serum. The cells are inoculated at a concentration of about  $1 \cdot 10^4$  cells/ml and cultured at 37°C in an atmosphere of 5% carbon dioxide/95% air. Since the cells generally become a confluent state 2 to 3 days thereafter, the medium is changed to serum-free D-MEM at that stage. By further carrying out 2 to 3 days of culturing, a culture mixture containing the protein of interest can be obtained. In this connection, when the amount of the produced protein of interest is small, it is possible to increase the production by amplifying the gene with methotrexate as described in the foregoing.

[0131] Purification of the novel Fas antigen derivative of the first aspect of the present invention from the aforementioned culture mixture is carried out by optionally selecting appropriate means from those which are generally used in the purification of polypeptides. Illustratively, the purification may be carried out by optionally combining appropriate means selected from usually used techniques such as salting-out, ultrafiltration, isoelectric precipitation, gel filtration, electrophoresis, ion exchange chromatography, hydrophobic chromatography, antibody chromatography and the like various affinity chromatographic techniques, chromatofocusing, adsorption chromatography, reverse phase chromatography and the like, if necessary further using a HPLC system and the like. Particularly, an affinity chromatography which uses an anti-Fas antibody capable of recognizing the novel Fas antigen derivative of the present invention, a Fas ligand, protein A or the like as the ligand is also useful for the purification of said novel polypeptide.

[0132] In said production method, the novel Fas antigen derivative of the first aspect of the present invention may be expressed as a fusion protein with *E. coli*  $\beta$ -galactosidase or other polypeptide, but, in that case, it is necessary to employ a step to cut off said protein by its treatment with cyanogen bromide, hydroxylamine or the like chemical substance or a protease or the like enzyme in any one of the purification steps.

[0133] Also, when the used transformant is *E. coli* and said protein is produced as an insoluble protein in the form of inclusion body, a procedure in which the inclusion body is subjected to solubilization, denaturation and refolding in that order may be carried out in an appropriate step of the purification (Thomas E. and Creighton J., *J. Molecular Biology*, vol. 87, pp. 563 - 577, 1974).

[0134] Illustratively, the cells are disrupted and centrifuged and the resulting pellet is recovered. Next, a solubilization buffer containing appropriate amounts of urea or guanidine hydrochloride and a detergent, reduced form glutathione and oxidized form glutathione (for example, a buffer containing 5 M guanidine hydrochloride, 0.005% Tween 80, 50 mM Tris-HCl (pH 8.0), 5 mM EDTA, 2 mM reduced form glutathione and 0.02 mM oxidized form glutathione) is added to the pellet, the mixture is subjected to denaturation by adding 2-mercaptoethanol and then the resulting sample is subjected to refolding by dialyzing it against the solubilization buffer from which guanidine hydrochloride is eliminated in advance.



Then the product is expressed as a fusion protein, unnecessary moiety of the protein is cut off using cyanogen bromide or the like chemical substance or a protease or the like enzyme after these treatments and then an appropriate chromatography is carried out.

[0135] According to said production method, the novel Fas antigen derivative of the present invention having Fas antigen activities, which is useful in pharmaceutical preparations and the like, can be produced homogeneously with high efficiency in an industrial large scale.

[0136] Next, the medicament of the sixth aspect of the present invention is described. The medicament of the sixth aspect of the present invention contains the novel Fas antigen derivative of the first aspect or a physiologically acceptable salt thereof as its active ingredient.

[0137] Also, it can be made into a pharmaceutical composition by optionally adding pharmaceutically acceptable carriers, fillers, stabilizers, lubricants, coloring agents, disintegrating agents, antiseptics, tonicity agents, stabilizing agents, dispersing agents, antioxidants, buffers, preservatives, suspending agents, emulsifying agents and generally used appropriate solvents (sterilized water, plant oil and the like), as well as physiologically acceptable solubilizing agents and the like.

[0138] The medicament of the present invention can be used in various routes of administration of which parenteral administration is desirable. Examples of the parenteral administration include intravenous administration, intraarterial administration, subcutaneous administration, intramuscular administration and the like injections which are general, as well as rectal administration, percutaneous absorption, transmucosal absorption and the like. In this case, suppositories, inhalations, particularly injections and the like are desirable as the dosage form.

[0139] The medicament of the sixth aspect of the present invention can control excess apoptosis and therefore can prevent and treat various morbid states and diseases caused by abnormal apoptosis, by administering it to humans or animals suffering from abnormal Fas antigen-mediated apoptosis, particularly excess apoptosis induced by overproduction of endogenous Fas ligand under morbidity or overdose of exogenous Fas ligand. Effective content or dosage and formulation of the novel Fas antigen derivative or a physiologically acceptable salt thereof as the active ingredient are optionally decided depending on the morbid state.

[0140] The seventh aspect of the present invention is a method for improving the activity or function of the Fas antigen or Fas antigen derivative, which is characterized by the deletion of at least one of the amino acid residues starting from the N-terminal amino acid residue of the Fas antigen to a cysteine residue most close to the N-terminal side (excluding said cysteine residue). It also provides a method for designing, or a method for preparing, the Fas antigen or Fas antigen derivative having improved activity or function, which is characterized by the deletion of at least one of the 1st to 42nd amino acid residues counting from the N-terminus of the Fas antigen. Said preparation method comprises the steps of producing the novel Fas antigen derivative of the first aspect of the present invention and confirming the improvement by measuring its activity and the like. A method for selecting amino acid residues to be deleted from the N-terminal region, a method for producing a polypeptide having said deletion and a method for measuring the activity are as described in the foregoing.

## EXAMPLES

[0141] The following examples are provided for further illustration of the present invention, but the examples are for purpose of illustration only and are not intended as a definition of the limits of the invention. Also, the abbreviations used in the following description are based on the commonly used abbreviations in said field. In this connection, various procedures employed in the following examples were carried out mainly with reference to the journals and books shown below.

1. Michael A.I. *et al.*, Polymerase Chain Reaction, PCR Protocols, a guide to methods and applications (1990), Academic Press
2. Sambrook J. *et al.*, Molecular Cloning, 2nd ed., Cold Spring Harbor Laboratory, New York, 1989
3. Genetic Engineering Handbook, a supplement of *Experimental Medicine*, published by Yodo-sha, Japan, on March 20, 1991
4. "Methods for Microbial Experiments", edited by Japanese Biochemical Society, published by Tokyo Kagaku Dojin, 1992
5. Methods for Immunological Experiments, edited by The Japanese Society for Immunology, published by The Japanese Society for Immunology
6. Fumio Imamoto *et al.*, "Introduction of Recombinant Genes into Cells and their Expression", *Protein, Nucleic Acid and Enzyme*, Supplement 28(14), 1983
7. Yoshio Okada, "General Cell Technology Techniques", *Experimental Medicine*, Supplement 7(13), 1989

## (Inventive Example 1) Preparation of novel polypeptide-expression vector

## (1) Preparation of plasmid pM1097

5 [0142] Sense primer 1 (CTGACTAGTGTGCTACTCAGAACTTGGAA) and antisense primer 2 (GTCAAGCTTGGTAC-  
CCTATTAGTTAGATCTGGATCCTTC) were chemically synthesized (Sequence ID Nos. 1 and 2 in the Sequence List-  
ing). This sense primer 1 contains *SpeI* site (ACTAGT), 3'-end region of a nucleotide sequence which encodes the  
human Fas antigen signal peptide and a nucleotide sequence that encodes 30th to 34th amino acids of human Fas anti-  
gen. On the other hand, the antisense primer 2 contains a nucleotide sequence which encodes the C-terminal side of  
10 the human Fas antigen extracellular region, *HindIII* site (AAGCTT) and *KpnI* site (GGTACC).

[0143] A 100  $\mu$ l portion of a solution was prepared which contained 100 pmol of each of the thus obtained sense  
primer 1 and antisense primer 2, 0.5  $\mu$ g of a plasmid pBLF58-1, which contains a DNA fragment coding for the human  
Fas antigen (Itoh N. et al., Cell, vol. 66, pp. 233 - 243, 1991), 20 nmol of each of dATP, dCTP, dGTP and dTTP, and 2.5  
units of Pfu DNA polymerase and 10  $\mu$ l of attached Pfu buffer (both manufactured by Stratagene). Using a DNA Ther-  
15 mal Cycler (PCR System 9600, manufactured by Perkin-Elmer Corp.), 30 cycles of PCR was carried out, each cycle  
being 30 seconds at 94°C, 30 seconds at 55°C and 1 minute at 72°C. The thus obtained PCR product was double-  
digested with *SpeI* and *HindIII*, the resulting DNA fragment of about 410 bp was integrated into *SpeI*, *HindIII* site of a  
plasmid pM1081 containing a DNA fragment disclosed in Example 21 of International Patent Application WO 95/13293,  
which encodes the human Fas antigen signal peptide and human Fas ligand extracellular region, and the thus obtained  
20 plasmid was named pM1097. This plasmid contains a DNA fragment represented by the nucleotide sequence of  
Sequence ID No. 12 of the Sequence Listing.

## (2) Preparation of plasmid pM1303

25 [0144] Firstly, sense primer 3 (TCACAAGCCCAGCAACACCAAG), antisense primer 4 (GCTTGCCGGCCGTCG-  
CACTC), sense primer 5 (GAAGGATCCAGATCTAACGAGCCCCAAATCTTGT) and antisense primer 6 (GTCGGTAC-  
CCTATCATTTACCCGGAGACAG) were chemically synthesized (Sequence ID Nos. 3, 4, 5 and 6 in the Sequence  
Listing). The sense primer 3 contains a nucleotide sequence which encodes C-terminal side of the CH1 region of  
human immunoglobulin G1, and the antisense primer 4 contains a sequence that encodes 3' non-translation region of  
30 human immunoglobulin G1. The sense primer 5 contains a nucleotide sequence which encodes C-terminal side amino  
acids of the human Fas antigen extracellular region, a nucleotide sequence that encodes N-terminal side amino acid  
sequence of the hinge region of human immunoglobulin G1 and *BamHI* site (GGATCC). The antisense primer 6 con-  
tains a nucleotide sequence which encodes a C-terminal side amino acid sequence of the CH3 region of human immu-  
noglobulin G1 and *KpnI* site (GCTACC). The PCR reaction was carried out under the same conditions of the step (1)  
35 by preparing 100  $\mu$ l of a solution which contains 100 pmol of each of the thus obtained sense primer 3 and antisense  
primer 4, 1  $\mu$ l of Human Spleen 5'-Stretch cDNA Library (manufactured by Clontech), 20 nmol of each of dATP, dCTP,  
dGTP and dTTP, and 2.5 units of Pfu DNA polymerase and 10  $\mu$ l of the attached Pfu buffer. Using the thus obtained  
PCR product of about 750 bp as the template, the PCR reaction was carried out in the same manner as described in  
the step (1) by preparing 100  $\mu$ l of a solution which contains 100 pmol of each of the sense primer 5 and antisense  
40 primer 6, 20 nmol of each of dATP, dCTP, dGTP and dTTP, and 2.5 units of Pfu DNA polymerase and 10  $\mu$ l of the  
attached Pfu buffer. The thus obtained PCR product was double-digested with *BamHI* and *KpnI*, the resulting DNA frag-  
ment of about 720 bp was integrated into *BamHI*, *KpnI* site of the plasmid pM1097 prepared in the step (1), and the  
thus obtained plasmid was named pM1303. This plasmid contains a DNA fragment represented by the nucleotide  
sequence of Sequence ID No. 14 of the Sequence Listing.

## (3) Preparation of plasmid pM1304

45 [0145] The plasmid pM1303 prepared in the step (2) was double-digested with *EcoRI* and *KpnI*, the resulting DNA  
fragment of about 1150 bp was integrated into *EcoRI*, *KpnI* site of a plasmid pM1103 modified by integrating the dhfr  
gene into pEF-BOS (Mizushima S. and Nagata S., Nucleic Acids Res., vol. 18, p. 5322, 1990), and the thus obtained  
50 plasmid was named pM1304. This plasmid is an expression vector of a polypeptide composed of the amino acid  
sequence of Sequence ID No. 11 of the Sequence Listing (to be referred to as shFas(nd29)-Fc herein in some cases).

## (4) Preparation of plasmid pM1317

55 [0146] Firstly, sense primer 7 (TGCGAATTCACCATGCTGGGCATCTGG) and antisense primer 8 (CGGGGTACCT-  
CACTATGGGCACGGTGGGCA) were chemically synthesized (Sequence ID Nos. 7 and 8 in the Sequence Listing).  
This sense primer 7 contains *EcoRI* site (GGATCC) and 5'-end region of a sequence which encodes the human Fas

antigen signal peptide. The antisense primer 8 contains a nucleotide sequence which encodes the C-terminal side amino acids of the hinge region of human immunoglobulin G1 and *KpnI* site (GGTACC). The PCR reaction was carried out in the same manner as described in the step (1) by preparing 100  $\mu$ l of a solution which contains 100 pmol of each of the thus obtained sense primer 7 and antisense primer 8, 0.3  $\mu$ g of the plasmid 1304 prepared in (3), 20 nmol of each of dATP, dCTP, dGTP and dTTP, and 2.5 units of Pfu DNA polymerase and 10  $\mu$ l of the attached Pfu buffer. The thus obtained PCR product was double-digested with *EcoRI* and *KpnI*, the resulting DNA fragment of about 450 bp was integrated into *EcoRI*, *KpnI* site of the plasmid pM1103 used in the step (3), and the thus obtained plasmid was named pM1317. This plasmid is an expression vector of a polypeptide composed of the amino acid sequence of Sequence ID No. 10 of the Sequence Listing (to be referred to as shFas(nd29)-hinge herein in some cases). In this connection, an *E. coli* strain JM109 was transformed with the plasmids pM1304 and pM1317 in the usual way, and the thus obtained transformants JM109(pM1304) and JM109(pM1317) have been deposited by the present inventors in National Institute of Bioscience and Human Technology, Higashi-1-1-3, Tsukuba-shi, Ibaraki, Japan, on March 14, 1996, which have been transferred on March 6, 1997, under the Budapest Treaty (FERM BP-5854 and FERM BP-5855).

#### (Inventive Example 2) Preparation and culturing of transformant

[0147] Using pM1304, pM1317 and pBF-Fc1 which has been described in Example 1 of International Patent Application WO 95/13293 (an expression plasmid of a chimera protein (to be referred to as hFas-Fc herein in some cases) of the extracellular region of human Fas antigen and Fc region of human IgG1), transformants COS-1/pM1304, COS-1/pM1317 and COS-1/pBF-Fc1 were prepared in the following manner. That is, 100  $\mu$ g of each plasmid DNA was dissolved in 500  $\mu$ l of a 10 mM Tris-HCl (pH 7.4)/1 mM ethylenediaminetetraacetic acid solution (to be referred to as TE buffer hereinafter). To each of the resulting solutions was added 125 ml of D-MEM (Nissui Pharmaceutical) containing 0.2 mg/ml of DEAE-dextran and 50 mM Tris-HCl (pH 7.4), thereby obtaining a DNA-DEAE-dextran mixture solution. The DNA-DEAE-dextran mixture solution was added to COS-1 cells which have been monolayer-cultured to their semi-confluent state using a 1,700 cm<sup>2</sup> capacity roller bottle (manufactured by Corning), and the cells were cultured at 37°C to obtain the transformants COS-1/pM1304, COS-1/pM1317 and COS-1/pBF-Fc1. After 4 hours of the culturing, the DNA-DEAE-dextran mixture solution was removed and replaced by D-MEM medium containing 10% fetal calf serum (manufactured by Lifetech Oriental), and the cells were cultured for additional 24 hours. Thereafter, the medium was changed to phenol red free D-MEM (no addition of FBS and BSA), the cells were again cultured for 72 hours and then the culture supernatant was recovered.

#### (Inventive Example 3) Purification of shFas(nd29)-Fc

##### (1) Affinity chromatography

[0148] Ammonium sulfate (mfd. by Wako Pure Chemical Industries) was added to, and dissolved in, one liter of COS-1/pM1304 culture supernatant to 70% saturation, and the solution was allowed to stand overnight at 4°C. The thus formed precipitate was recovered by 30 minutes of centrifugation at 8,000 rpm and at 4°C, suspended in phosphate-buffered saline (PBS) and then dialyzed against PBS. A 57 ml portion of the thus prepared suspension was diluted with two volumes of Affi-prep Protein A Binding Buffer (manufactured by Bio-Rad). After removing the insoluble matter by filtration, the resulting solution was applied to an Affi-prep Protein A Preparative Cartridge (7.3 ml, manufactured by Bio-Rad) column which has been equilibrated in accordance with the instructions. The column was washed with 90 ml of Affi-prep Protein A Binding Buffer and then shFas(nd29)-Fc was eluted with Affi-prep Protein A Elution Buffer (manufactured by Bio-Rad). Fractions containing shFas(nd29)-Fc which was detected by ELISA making use of a monoclonal antibody specific for human Fas antigen were pooled, subjected to ultrafiltration using Filtron Omega Cell (manufactured by Fuji Filter; nominal molecular weight cutoff of 30 kD) and then concentrated. The thus concentrated solution was dialyzed against 0.9% NaCl, thereby obtaining purified shFas(nd29)-Fc. Also, hFas-Fc was purified in the same manner. The protein content of each sample was measured in accordance with the method of Lowry using bovine serum albumin as the standard substance.

##### (2) SDS-PAGE

[0149] The purified shFas(nd29)-Fc obtained in the above step (1) was subjected to polyacrylamide gel electrophoresis using a 5 to 20% gradient gel containing 0.1% SDS, and the band was detected by staining the gel with 2D-Silver Staining Reagent II "Daiichi" (manufactured by Daiichi Pure Chemicals). Results of the purification of shFas(nd29)-Fc are shown in Fig. 6. In the drawing, lanes 1 to 4 show results under a non-reducing condition, and lanes 5 to 8 under a reducing condition. As shown in Fig. 6, the purified shFas(nd29)-Fc was detected as an almost single band corresponding to its dimer having a molecular weight of about 85 kD under the non-reducing condition (lanes 1 to 3) or correspond-

ing to its monomer having a molecular weight of about 43 kD under the reducing condition (lanes 5 to 7).

(Inventive Example 4) Analysis of shFas(nd29)-Fc N-terminal amino acid sequence

5 (1) Desalting of test sample by reverse phase HPLC

[0150] The purified shFas(nd29)-Fc obtained in Inventive Example 3 was subjected to a reverse phase HPLC in the following manner. Firstly, the aforementioned purified shFas(nd29)-Fc was applied to a VYDAC C4 column (4.6 mmØ x 25 cm, manufactured by Cypress) which had been equilibrated with 0.05% trifluoroacetic acid in advance, and the column was then washed with 0.05% trifluoroacetic acid. After the washing, elution was carried out by a linear density gradient method at a flow rate of 1 ml/min using 0.05% trifluoroacetic acid/0-100% acetonitrile.

(2) Analysis of N-terminal amino acid sequence

15 [0151] The eluted main peak fraction was lyophilized and dissolved in 70% formic acid, and N-terminal amino acid sequence of the thus prepared sample was determined using Model 477A Protein Sequencing System-120 APTH Analyzer (manufactured by Perkin-Elmer). That is, PTH amino acids were detected at an ultraviolet absorption of 270 nm, and the amino acids were identified based on the retention time of standard PTH amino acids (manufactured by Perkin-Elmer) which have been isolated in advance by the same method. As the results, it was confirmed that the sample has  
20 an N-terminal amino acid sequence (Thr Gln Asn Leu Glu Gly Leu His His Asp) in which 29 amino acid residues are deleted from the N-terminus of human Fas antigen.

(Inventive Example 5) Comparison of apoptosis inhibition activities of shFas(nd29)-Fc and hFas-Fc

25 [0152] The measurement was carried out based on the activity of shFas(nd29)-Fc and hFas-Fc to inhibit cytotoxic activities of 1A12 cells and FLm14 cells upon WC8 cells and W4 cells. The 1A12 cells are cells obtained by transforming mouse WR19L cells to express human Fas ligand, and the FLm14 cells are cells obtained by transforming mouse FDC-P1 cells to express mouse Fas ligand. The WC8 cells and W4 cells are cells obtained by transforming mouse WR19L cells to express human Fas antigen and mouse Fas antigen, respectively. The WR19L cells are cells which can  
30 hardly express mouse Fas antigen and are sensitive to the cytotoxicity of TNF. Measurement of the cytotoxic activity was carried out in accordance with the method of Rouvier E. *et al.* (*J. Exp. Med.*, vol. 177, pp. 195 - 200, 1993). Firstly, 1A12 cells or FLm14 cells were washed with RPMI 1640 containing 10% of immobilized FBS and used as the effector cells. On the other hand,  $1 \times 10^6$  of WC8 cells or W4 cells were incubated at 37°C for 2 hours in 100 µl of RPMI 1640 containing 10% of immobilized FBS together with 20 µCi of [ $^{51}\text{Cr}$ ] sodium chromate (manufactured by NEN). After  
35 washing with RPMI 1640 containing 10% of immobilized FBS, these cells were used as the target cells. Together with varied amounts of shFas(nd29)-Fc and hFas-Fc,  $1 \times 10^4$  of 1A12 cells or  $1 \times 10^5$  of FLm14 cells were mixed with  $1 \times 10^4$  of the target cells in each round bottom well of a microtiter plate. In this case, the total liquid volume was adjusted to 100 µl. The thus prepared plate was centrifuged at 800 rpm for 2 minutes and then incubated at 37°C for 4 hours. Thereafter, the plate was centrifuged at 1,200 rpm for 5 minutes, and a 50 µl portion of the supernatant was collected  
40 from each well to measure the radioactivity using a γ counter, thereby calculating specific cell lysis ratio. Spontaneous release of  $^{51}\text{Cr}$  was determined by incubating the target cells in the medium alone, and its maximum release was determined by adding Triton X-100 to the target cells to a concentration of 0.1%. The specific cell lysis ratio was calculated by the following formula.

45 Specific cell lysis ratio (%)

$$= \frac{\text{observed release of } ^{51}\text{Cr} - \text{spontaneous release of } ^{51}\text{Cr}}{\text{maximum release of } ^{51}\text{Cr} - \text{spontaneous release of } ^{51}\text{Cr}} \times 100$$

50

[0153] Fig. 9 shows specific cytotoxicity inhibition activities of shFas(nd29)-Fc and hFas-Fc when 1A12 cells were used as the effector cells and WC8 cells as the target cells, and Fig. 10 shows specific cytotoxicity inhibition activities of shFas(nd29)-Fc and hFas-Fc when FLm14 cells were used as the effector cells and W4 cells as the target cells. As  
55 shown in Figs. 9 and 10, shFas(nd29)-Fc was possessed of 3 to 10 times higher cytotoxicity inhibition activity than that of Fas-Fc.

## (Inventive Example 6) Purification of shFas(nd29)-hinge

## (1) Preparation of anti-Fas antigen monoclonal antibody-immobilized affinity column

5 [0154] A 350 mg portion of an anti-Fas antigen monoclonal antibody (4B4-B3) which has been prepared in accordance with a known method (Kohler and Milstein, *Nature*, vol. 256, p. 495, 1975) using mouse myeloma cells and spleen cells of mouse immunized with human Fas antigen was mixed with 120 ml of Formyl-Cellulofine (manufactured by Seikagaku Kogyo) and stirred at 4°C for 2 hours. This was then mixed with 650 mg of trimethylamine borane (manufactured by Wako Pure Chemical Industries) and stirred overnight to effect binding of the antibody. In order to remove un-immobilized antibody molecules, the resin was washed with 2.4 liters of ultra-pure water. Thereafter, this was stirred at 4°C  
10 for 3 hours in 0.2 M Tris-HCl (pH 8.0) together with 650 mg of trimethylamine borane to block unreacted formyl group, thereby obtaining the antibody affinity column.

## (2) Affinity chromatography

15 [0155] A ten liter portion of COS-1/pM1317 culture supernatant was concentrated to 1.5 liters by ultrafiltration using Filtron Mini Set (manufactured by Fuji filter; 10 kD in nominal molecular weight cutoff). Thereafter, the concentrate was adjusted to pH 8.0 by adding 1 M Tris-HCl (pH 9.0) and applied to the anti-Fas antigen monoclonal antibody-immobilized affinity column which has been equilibrated in advance with 50 mM Tris-HCl 320ml of (pH 8.0) containing 1 M  
20 NaCl. After washing the column with 50 mM Tris-HCl (pH 8.0) containing 1 M NaCl, shFas(nd29)-hinge was eluted with 0.1 M glycine-HCl (pH 2.5) containing 1 M NaCl. Fractions containing shFas(nd29)-hinge detected by ELISA were pooled, subjected to ultrafiltration using Filtron Omega Cell (manufactured by Fuji filter; 10 kD in nominal molecular weight cutoff) and then concentrated. By dialyzing the concentrate against 0.9% NaCl, purified shFas(nd29)-hinge was obtained.

## (3) SDS-PAGE

25 [0156] The purified shFas(nd29)-hinge obtained in the above step (2) was subjected to polyacrylamide gel electrophoresis using a 5 to 20% gradient gel containing 0.1% SDS, and the band was detected by staining the gel with 2D-Silver Staining Reagent II "Daiichi" (manufactured by Daiichi Pure Chemicals). Results of the purification of shFas(nd29)-hinge are shown in Fig. 7. In the drawing, lane 1 shows results under a non-reducing condition, and lane 2 under a reducing condition. As shown in Fig. 7, the purified shFas(nd29)-hinge was detected as two bands having molecular weights of about 43 kD and about 27 kD under the non-reducing condition or as two bands having molecular weights of about 23 kD and 27 kD under the reducing condition.  
30

## (4) Gel filtration chromatography

35 [0157] Gel filtration of the shFas(nd29)-hinge obtained in Inventive Example 6 (2) was carried out by applying it to Sephadex 75 column (manufactured by Pharmacia) which has been equilibrated in advance with 50 mM Tris-HCl/0.5 M NaCl (pH 8.0) and then eluting it with 50 mM Tris-HCl/0.5 M NaCl (pH 8.0), and the fractionation was effected using absorbance at 214 nm as the indicator. In the same manner as described in Inventive Example 6 (2), each fraction was concentrated and subjected to polyacrylamide gel electrophoresis. As shown in Fig. 8, it was able to separate a band which was contained in the higher molecular weight fraction (fractions 1 and 2) and seemed to be corresponding to a dimer from another band which was contained in the lower molecular weight fraction (fractions 3 and 4) and seemed to be corresponding to a monomer. Though both fractions showed the cytotoxicity inhibition activity by the assay described in Inventive Example 8, the high molecular weight side fraction showed more stronger activity (about 50 times or more).  
45

## (Inventive Example 7) Analysis of shFas(nd29)-hinge N-terminal amino acid sequence

50 [0158] Using the purified shFas(nd29)-hinge obtained in Inventive Example 6 (2), its N-terminal amino acid sequence was determined using Model 477A Protein Sequencing System-120 APTH Analyzer (manufactured by Perkin-Elmer). That is, PTH amino acids were detected at an ultraviolet absorption of 270 nm, and the amino acids were identified based on the retention time of standard PTH amino acids (manufactured by Perkin-Elmer) which have been isolated in advance by the same method. As the results, it was confirmed that the sample has an N-terminal amino acid sequence  
55 in which 29 amino acid residues are deleted from the N-terminus of human Fas antigen.

(Inventive Example 8) Comparison of apoptosis inhibition activities of shFas(nd29)-hinge and hFas-Fc

[0159] The activity of shFas(nd29)-hinge and hFas-Fc to inhibit cytotoxic activities of 1A12 cells and FLm14 cells upon WC8 cells and W4 cells was measured in the same manner as described in Inventive Example 5. Specific cytotoxicity inhibition activities of shFas(nd29)-hinge and hFas-Fc when 1A12 cells were used as the effector cells and WC8 cells as the target cells are shown in Fig. 11, and specific cytotoxicity inhibition activities of shFas(nd29)-hinge and hFas-Fc when FLm14 cells were used as the effector cells and W4 cells as the target cells are shown in Fig. 12. As shown in Figs. 11 and 12, shFas(nd29)-hinge was possessed of 3 to 10 times higher cytotoxicity inhibition activity than that of Fas-Fc.

(Inventive Example 9) Analysis of the structure in and around N-terminal region of the Fas antigen extracellular region

[0160] By constructing a steric structure model of the Fas antigen extracellular region, an analysis was made on the relationship between the deletion of amino acid residues in the N-terminal region and the Fas antigen-Fas ligand binding. Proteins having known steric structures and high homology with the amino acid sequence of the Fas antigen extracellular region were retrieved from the PROTEIN DATA BANK (PDB) which is a data base of biological high polymer three-dimensional structures, by the FASTA program in the Homology module manufactured by BIOSYM. As the results, it was found that the extracellular region of TNF receptor p55 (PDB-ID ITNR) has high homology in overall structure. Since this structure was in the form of a complex with TNF- $\beta$ , it was most suitable also as a reference protein in constructing a model structure of Fas antigen-Fas ligand complex. Also, the TNF- $\alpha$  (PDB-ID INTF) structure was used as a reference protein in the Fas ligand structure. Construction of the model structure was carried out by a homology modeling method using the Homology module manufactured by BIOSYM. The thus constructed initial structure model was subjected to an energy optimization computing (MM computing) using a molecular force field computing software, DISCOVERY, manufactured by BIOSYM to obtain a Fas antigen-Fas ligand complex model structure. Next, since a part of the N-terminal region of the thus obtained structure could not be generated from the coordinates of the reference protein, structural prediction of this part was carried out. A Fas antigen extracellular region monomer model structure was extracted from the complex structure, and the deleting 31 amino acid residues were automatically added to its N-terminus by the BIOPOLYMER module manufactured by BIOSYM to minimize the structure. Next, molecular dynamics computing (MD computing) of 1,000 K and 100 pico-seconds was carried out *in vacuo*, and structures for every 10 pico-seconds were sampled. Each of the thus sampled structures was minimized to be used as the final Fas antigen extracellular region monomer model structure. Then these structures were again made into its complex with the Fas ligand model structure, it was predicted that the N-terminal structure of the Fas antigen extracellular region could cause steric hindrance for its binding with the Fas ligand. On the other hand, when the nd29 model structure was subjected to a simulation analysis by MD computing, it was predicted that it could bind to Fas ligand more quickly, because greater part of the structure hindering its binding with Fas ligand was found to be deleted. In addition, an analysis was made on the state of steric hindrance in complex models of a plurality of conformations of the sampled structure with the Fas ligand structure. As the results, it was predicted that, within the range of from the 1st position arginine residue to the 31st position glutamine residue counting from the N-terminus of Fas antigen, degree of the steric hindrance would be reduced with the deletion of more amino acid residues, and apoptosis inhibition activity of the extracellular region of Fas antigen would increase when particularly 13 or 18 or more amino acid residues were deleted. It was predicted also that increase in the activity could hardly be expected by a deletion within the range of from the 36th position leucine residue to the 42nd position phenylalanine residue counting from the N-terminus, and deletion of the 43rd position cysteine residue counting from the N-terminus of Fas antigen would result in the loss of apoptosis inhibition activity due to destruction of the secondary structure formed by the antigen. The three-dimensional structure analysis carried out this time showed that the affinity for Fas ligand can be controlled by cutting N-terminal structure of the Fas antigen extracellular region.

(Inventive Example 10) Mouse hepatopathy inhibition by shFas(nd29)-Fc

[0161] C57BL/6Cr S1c mice (males, 9 weeks of age, purchased from Japan S L C) were divided into 3 groups, 5 animals per group, and used as the animals to be tested. Cells of *Propionibacterium acnes* killed with heat (manufactured by RIBI Immunochemical Corp.) were dissolved in physiological saline (manufactured by Otsuka Pharmaceutical) to a concentration of 1.5 mg/ml, and a 0.2 ml portion of the resulting solution was administered to each of the mice via tail vein. After 8 days of the administration, the shFas(nd29)-Fc prepared in Inventive Example 3 was diluted with a diluent solution (physiological saline containing 0.1% human serum albumin (The Chemo-Sero-Therapeutic Research Institute)) and administered via tail vein in a dosage of 0.3 mg/8 ml/kg or 1 mg/8 ml/kg. The diluent solution alone was administered to the control group. Five minutes thereafter, 0.2 ml of a lipopolysaccharide (manufactured by Sigma) solution prepared by adjusting to a concentration of 5  $\mu$ g/ml with physiological saline was administered intraperitoneally. After 8 or 24 hours of the lipopolysaccharide administration, 75  $\mu$ l of blood was collected from the fundus oculi vein. The

thus collected blood was mixed with 8.3  $\mu$ l of 3.8% sodium citrate (manufactured by Wako Pure Chemical Industries) aqueous solution and centrifuged at 3,000 rpm for 10 minutes. After the centrifugation, the thus obtained blood plasma was frozen with liquid nitrogen and stored at -30°C until its use. Measurement of GOT and GPT were carried out using GOT-FA Test Wako (manufactured by Wako Pure Chemical Industries), GPT-FA Test Wako (manufactured by Wako Pure Chemical Industries) and an automatic analyzer (Cobasfara, manufactured by Roche). As the results, the GOT and GPT values in a test group in which 1 mg/8 ml/kg of shFas(nd29)-Fc was administered were lower than those of the control group, thus confirming its hepatopathy inhibition effect (Fig. 13).

(Inventive Example 11) Mouse hepatopathy inhibition action of shFas(nd29)-hinge

[0162] C57BL/6Cr S1c mice (males, 9 weeks of age, purchased from Japan S L C) were divided into 4 groups, 5 animals per group, and used as the animals to be tested. Cells of *Propionibacterium acnes* killed with heat (manufactured by RIBI Immunochemical Corp.) were dissolved in physiological saline (manufactured by Otsuka Pharmaceutical) to a concentration of 1.5 mg/ml, and a 0.2 ml portion of the resulting solution was administered to each of the mice via tail vein. After 8 days of the administration, the shFas(nd29)-hinge prepared in Inventive Example 6 was diluted with a diluent solution (physiological saline containing 0.1% human serum albumin (The Chemo-Sero-Therapeutic Research Institute)) and administered via tail vein in a dosage of 0.3 mg/8 ml/kg, 1 mg/8 ml/kg or 3 mg/8 ml/kg. The diluent solution alone was administered to the control group. Five minutes thereafter, 0.2 ml of a lipopolysaccharide (manufactured by Sigma) solution prepared by adjusting to a concentration of 5  $\mu$ g/ml with physiological saline was administered intraperitoneally. After 8 or 24 hours of the lipopolysaccharide administration, 75  $\mu$ l of blood was collected from the fundus oculi vein. The thus collected blood was mixed with 8.3  $\mu$ l of 3.8% sodium citrate (manufactured by Wako Pure Chemical Industries) aqueous solution and centrifuged at 3,000 rpm for 10 minutes. After the centrifugation, the thus obtained blood plasma was frozen with liquid nitrogen and stored at -30°C until its use. Measurement of GOT and GPT were carried out using GOT-FA Test Wako (manufactured by Wako Pure Chemical Industries), GPT-FA Test Wako (manufactured by Wako Pure Chemical Industries) and an automatic analyzer (Cobasfara, manufactured by Roche). As the results, the GOT and GPT values in the shFas(nd29)-hinge-administered groups were lower than those of the control group, thus confirming its hepatopathy inhibition effect (Fig. 14).

#### INDUSTRIAL APPLICABILITY

[0163] Since the novel polypeptide (novel Fas antigen derivative) of the present invention can inhibit induction of apoptosis by competitively inhibiting binding of a Fas ligand with a Fas antigen, it can be used for the prevention and treatment of various diseases in which the participation of apoptosis mediated by the Fas antigen is indicated, by controlling the apoptosis mediated by the Fas antigen, particularly an apoptosis generated in the living body caused by an endogenous or exogenous Fas ligand. For example, in the case of certain autoimmune diseases, it will become possible to prevent destruction of organs by inhibiting rapid cell death caused by the attack of autoantigen reactive T cells, through the artificial inhibition of apoptosis making use of the novel Fas antigen derivative. Illustrative examples of such diseases include graft versus host disease (GVHD) and diabetes. It is known that not only infected cells but also uninfected cells are removed by immune reactions when infected with viruses. For example, it is considered that decrease in the immunological capacity at the latter stage of AIDS virus infection and reduction of liver functions by hepatitis, particularly fulminant hepatitis, are results of extreme reduction of tissue functions caused by the apoptosis of immunocytes or hepatocytes. In the case of such conditions, the novel Fas antigen derivative capable of inhibiting apoptosis can be used for the treatment of apoptosis-related infectious diseases caused by viruses, such as influenza, AIDS, hepatitis and the like, and complications thereof. In addition, since Fas antigen seems to be related to the cell death in various organs because of its broad distribution in organs, it may also be useful for the treatment of myocardopathy in myocardial infarction and the like ischemic heart diseases, such as reperfusion injury, nephritis and multiple organ failure and for the preservation organs at the time of organ transplantation. Particularly, since the novel Fas antigen derivative of the present invention can strongly inhibit apoptosis with a low dosage, it will also be effective in the living body with a low dosage and with less side effects, so that it has high availability from the viewpoint of efficacy, safety and cost. The novel Fas antigen derivative of the present invention which comprises a sequence of human origin is particularly desirable in applying it to human.

[0164] Also, the novel Fas antigen derivative which can induce apoptosis when appropriately incorporated into cells is effective in accelerating apoptosis by properly incorporating it into cells in the liposomes or the like form or by properly expressing it on cells by means of gene therapy for example using the DNA of the second aspect of the present invention. In consequence, it is effective in removing unnecessary cells such as virus-infected cells in the early stage of viral infection and also can be used for the prevention and treatment of diseases which seem to be caused by a failure in apoptosis, such as articular rheumatism, SLE and the like.

[0165] Also, since it keeps at least a part of the antigenicity of Fas antigen, it can be linked to an anti-Fas antigen

antibody, so that it is effective in inhibiting apoptosis caused by the anti-Fas antigen-antibody.

5 [0166] Also, since the novel Fas antigen derivative of the present invention binds to Fas ligand with more specific and high affinity, it can be applied to the detection of Fas ligand in human body fluids. Since it can be used for the detection of increment, reduction or abnormality of Fas ligand in various diseases in which the participation of Fas ligand is indicated, it can be applied to the precognition, detection and diagnosis of specific diseases and morbid states and to the selection of therapeutic methods thereof. It is also useful in monitoring patients undergoing medical treatment with Fas ligand, Fas ligand-related substances or drugs which exert influences upon the expression of Fas ligand, and in judging therapeutic effects and prognosis.

10 [0167] On the other hand, the DNA of the second aspect of the present invention and the like are useful for the large scale industrial production of the novel Fas antigen derivative with high purity. Because of this, the novel Fas antigen derivative can be supplied to the field of medicaments as a principal component of therapeutic drugs and also can be applied to diagnostic drugs. In addition, the nucleotide sequence which encodes the novel Fas antigen derivative can be applied to gene therapy and the like.

15

20

25

30

35

40

45

50

55



SEQUENCE LISTING

5

Sequence ID No.: 1

Sequence Length: 30

10

Sequence Type: nucleic acid

Molecular Type: other nucleic acid, synthetic DNA (sense primer 1)

15

Sequence:

CTGACTAGTG TCGCTACTCA GAACTTGGAA 30

20

Sequence ID No.: 2

Sequence Length: 39

25

Sequence Type: nucleic acid

Molecular Type: other nucleic acid, synthetic DNA (antisense primer  
2)

30

Sequence:

GTCAAGCTTG GTACCCTATT AGTTAGATCT GGATCCTTC 39

35

Sequence ID No.: 3

40

Sequence Length: 22

Sequence Type: nucleic acid

Molecular Type: other nucleic acid, synthetic DNA (sense primer 3)

45

Sequence:

TCACAAGCCC AGCAACACCA AG 22

50

55

Sequence ID No.: 4

5 Sequence Length: 20

Sequence Type: nucleic acid

10 Molecular Type: other nucleic acid, synthetic DNA (antisense primer  
4)

Sequence:

15 GCTTGCCGGC CGTCGCACTC 20

Sequence ID No.: 5

20 Sequence Length: 33

Sequence Type: nucleic acid

25 Molecular Type: other nucleic acid, synthetic DNA (sense primer 5)

Sequence:

30 GAAGGATCCA GATCTAACGA GCCCAAATCT TGT 33

Sequence ID No.: 6

35 Sequence Length: 30

Sequence Type: nucleic acid

40 Molecular Type: other nucleic acid, synthetic DNA (antisense primer  
6)

Sequence:

45 GTCGGTACCC TATCATTTAC CCGGAGACAG 30

50

55

Sequence ID No.: 7

Sequence Length: 27

Sequence Type: nucleic acid

Molecular Type: other nucleic acid, synthetic DNA (sense primer 7)

Sequence:

TGCGAATTCA CCATGCTGGG CATCTGG 27

Sequence ID No.: 8

Sequence Length: 30

Sequence Type: nucleic acid

Molecular Type: other nucleic acid, synthetic DNA (antisense primer 8)

Sequence:

CGGGGTACCT CACTATGGGC ACGGTGGGCA 30

Sequence ID No.: 9

Sequence Length: 128

Sequence Type: amino acid

Sequence:

Thr Gln Asn Leu Glu Gly Leu His His Asp Gly Gln Phe Cys His Lys

1 5 10 15

Pro Cys Pro Pro Gly Glu Arg Lys Ala Arg Asp Cys Thr Val Asn Gly

20 25 30

Asp Glu Pro Asp Cys Val Pro Cys Gln Glu Gly Lys Glu Tyr Thr Asp

35 40 45

5                    50                    55                    60  
 Lys Ala His Phe Ser Ser Lys Cys Arg Arg Cys Arg Leu Cys Asp Glu  
 Gly His Gly Leu Glu Val Glu Ile Asn Cys Thr Arg Thr Gln Asn Thr  
 10                    65                    70                    75                    80  
 Lys Cys Arg Cys Lys Pro Asn Phe Phe Cys Asn Ser Thr Val Cys Glu  
 85                    90                    95  
 15 His Cys Asp Pro Cys Thr Lys Cys Glu His Gly Ile Ile Lys Glu Cys  
 100                    105                    110  
 20 Thr Leu Thr Ser Asn Thr Lys Cys Lys Glu Glu Gly Ser Arg Ser Asn  
 115                    120                    125

25                    Sequence ID No.: 10

Sequence Length: 143

Sequence Type: amino acid

30                    Sequence:

Thr Gln Asn Leu Glu Gly Leu His His Asp Gly Gln Phe Cys His Lys

35                    1                    5                    10                    15  
 Pro Cys Pro Pro Gly Glu Arg Lys Ala Arg Asp Cys Thr Val Asn Gly

40                    20                    25                    30  
 Asp Glu Pro Asp Cys Val Pro Cys Gln Glu Gly Lys Glu Tyr Thr Asp

45                    35                    40                    45  
 Lys Ala His Phe Ser Ser Lys Cys Arg Arg Cys Arg Leu Cys Asp Glu

50                    50                    55                    60  
 Gly His Gly Leu Glu Val Glu Ile Asn Cys Thr Arg Thr Gln Asn Thr  
 65                    70                    75                    80

Lys Cys Arg Cys Lys Pro Asn Phe Phe Cys Asn Ser Thr Val Cys Glu

85

90

95

His Cys Asp Pro Cys Thr Lys Cys Glu His Gly Ile Ile Lys Glu Cys

100

105

110

Thr Leu Thr Ser Asn Thr Lys Cys Lys Glu Glu Gly Ser Arg Ser Asn

115

120

125

Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro

130

135

140

Sequence ID No.: 11

Sequence Length: 360

Sequence Type: amino acid

Sequence:

Thr Gln Asn Leu Glu Gly Leu His His Asp Gly Gln Phe Cys His Lys

1

5

10

15

Pro Cys Pro Pro Gly Glu Arg Lys Ala Arg Asp Cys Thr Val Asn Gly

20

25

30

Asp Glu Pro Asp Cys Val Pro Cys Gln Glu Gly Lys Glu Tyr Thr Asp

35

40

45

Lys Ala His Phe Ser Ser Lys Cys Arg Arg Cys Arg Leu Cys Asp Glu

50

55

60

Gly His Gly Leu Glu Val Glu Ile Asn Cys Thr Arg Thr Gln Asn Thr

65

70

75

80

Lys Cys Arg Cys Lys Pro Asn Phe Phe Cys Asn Ser Thr Val Cys Glu

85

90

95

His Cys Asp Pro Cys Thr Lys Cys Glu His Gly Ile Ile Lys Glu Cys  
 5                   100                   105                   110  
 Thr Leu Thr Ser Asn Thr Lys Cys Lys Glu Glu Gly Ser Arg Ser Asn  
                   115                   120                   125  
 10 Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala  
                   130                   135                   140  
 15 Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro  
                   145                   150                   155                   160  
 Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val  
 20                   165                   170                   175  
 Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val  
                   180                   185                   190  
 25 Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln  
                   195                   200                   205  
 30 Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln  
                   210                   215                   220  
 35 Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala  
                   225                   230                   235                   240  
 Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro  
 40                   245                   250                   255  
 Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr  
                   260                   265                   270  
 45 Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser  
                   275                   280                   285  
 50 Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr  
                   290                   295                   300  
 55

Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr

305 310 315 320

Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe

325 330 335

Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys

340 345 350

Ser Leu Ser Leu Ser Pro Gly Lys

355 360

Sequence ID No.: 12

Sequence Length: 384

Sequence Type: nucleic acid

Molecular Type: cDNA to mRNA

Sequence:

ACTCAGAACT TGGAAGGCCT GCATCATGAT GGCCAATTCT GCCATAAGCC CTGTCCTCCA 60  
GGTGAAAGGA AAGCTAGGGA CTGCACAGTC AATGGGGATG AACCAGACTG CGTGCCCTGC 120  
CAAGAAGGGA AGGAGTACAC AGACAAAGCC CATT TTTTCTT CCAAATGCAG AAGATGTAGA 180  
TTGTGTGATG AAGGACATGG CTTAGAAGTG GAAATAAACT GCACCCGGAC CCAGAATACC 240  
AAGTGCAGAT GTAAACCAAA CTTTTTTTGT AACTCTACTG TATGTGAACA CTGTGACCCT 300  
TGCACCAAAT GTGAACATGG AATCATCAAG GAATGCACAC TCACCAGCAA CACCAAGTGC 360  
AAAGAGGAAG GATCCAGATC TAAC 384

Sequence ID No.: 13

Sequence Length: 429

Sequence Type: nucleic acid

Molecular Type: cDNA to mRNA

Sequence:

5 ACTCAGAACT TGGAAGGCCT GCATCATGAT GGCCAATTCT GCCATAAGCC CTGTCCTCCA 60  
GGTGAAAGGA AAGCTAGGGA CTGCACAGTC AATGGGGATG AACCAGACTG CGTGCCCTGC 120  
CAAGAAGGGA AGGAGTACAC AGACAAAGCC CATT TTTTCTT CCAAATGCAG AAGATGTAGA 180  
10 TTGTGTGATG AAGGACATGG CTTAGAAGTG GAAATAAACT GCACCCGGAC CCAGAATACC 240  
AAGTGCAGAT GTAAACCAAA CTTTTTTTGT AACTCTACTG TATGTGAACA CTGTGACCCT 300  
TGCACCAAAT GTGAACATGG AATCATCAAG GAATGCACAC TCACCAGCAA CACCAAGTGC 360  
15 AAAGAGGAAG GATCCAGATC TAACGAGCCC AAATCTTGTG ACAA AACTCA CACATGCCCA 420  
CCGTGCCCA 429

Sequence ID No.: 14

Sequence Length: 1080

Sequence Type: nucleic acid

Molecular Type: cDNA to mRNA

Sequence:

30 ACTCAGAACT TGGAAGGCCT GCATCATGAT GGCCAATTCT GCCATAAGCC CTGTCCTCCA 60  
GGTGAAAGGA AAGCTAGGGA CTGCACAGTC AATGGGGATG AACCAGACTG CGTGCCCTGC 120  
35 CAAGAAGGGA AGGAGTACAC AGACAAAGCC CATT TTTTCTT CCAAATGCAG AAGATGTAGA 180  
TTGTGTGATG AAGGACATGG CTTAGAAGTG GAAATAAACT GCACCCGGAC CCAGAATACC 240  
40 AAGTGCAGAT GTAAACCAAA CTTTTTTTGT AACTCTACTG TATGTGAACA CTGTGACCCT 300  
TGCACCAAAT GTGAACATGG AATCATCAAG GAATGCACAC TCACCAGCAA CACCAAGTGC 360  
AAAGAGGAAG GATCCAGATC TAACGAGCCC AAATCTTGTG ACAA AACTCA CACATGCCCA 420  
45 CCGTGCCCAG CACCTGAACT CCTGGGGGGA CCGTCAGTCT TCCTCTTCCC CCCAAAACCC 480  
AAGGACACCC TCATGATCTC CCGGACCCCT GAGGTCACAT GCGTGGTGGT GGACGTGAGC 540  
CACGAAGACC CTGAGGTCAA GTTCAACTGG TACGTGGACG GCGTGGAGGT GCATAATGCC 600  
50 AAGACAAAGC CGCGGGAGGA GCAGTACAAC AGCACGTACC GTGTGGTCAG CGTCCTCACC 660



GTCCTGCACC AGGACTGGCT GAATGGCAAG GAGTACAAGT GCAAGGTCTC CAACAAAGCC 720  
 5 CTCCCAGCCC CCATCGAGAA AACCATCTCC AAAGCCAAAG GGCAGCCCCG AGAACCACAG 780  
 GTGTACACCC TGCCCCATC CCGGGATGAG CTGACCAAGA ACCAGGTCAG CCTGACCTGC 840  
 CTGGTCAAAG GCTTCTATCC CAGCGACATC GCCGTGGAGT GGGAGAGCAA TGGGCAGCCG 900  
 10 GAGAACAAC TACAAGACCAC GCCTCCCGTG CTGGACTCCG ACGGCTCCTT CTTCCTCTAC 960  
 AGCAAGCTCA CCGTGGACAA GAGCAGGTGG CAGCAGGGGA ACGTCTTCTC ATGCTCCGTG 1020  
 15 ATGCATGAGG CTCTGCACAA CCACTACACG CAGAAGAGCC TCTCCCTGTC TCCGGGTAAA 1080

Sequence ID No.: 15

Sequence Length: 157

Sequence Type: amino acid

Sequence:

Arg Leu Ser Ser Lys Ser Val Asn Ala Gln Val Thr Asp Ile Asn Ser

1 5 10 15

Lys Gly Leu Glu Leu Arg Lys Thr Val Thr Thr Val Glu Thr Gln Asn

20 25 30

Leu Glu Gly Leu His His Asp Gly Gln Phe Cys His Lys Pro Cys Pro

35 40 45

Pro Gly Glu Arg Lys Ala Arg Asp Cys Thr Val Asn Gly Asp Glu Pro

50 55 60

Asp Cys Val Pro Cys Gln Glu Gly Lys Glu Tyr Thr Asp Lys Ala His

65 70 75 80

Phe Ser Ser Lys Cys Arg Arg Cys Arg Leu Cys Asp Glu Gly His Gly

85 90 95

Leu Glu Val Glu Ile Asn Cys Thr Arg Thr Gln Asn Thr Lys Cys Arg

100 105 110

Cys Lys Pro Asn Phe Phe Cys Asn Ser Thr Val Cys Glu His Cys Asp

5                    115                    120                    125

Pro Cys Thr Lys Cys Glu His Gly Ile Ile Lys Glu Cys Thr Leu Thr

130                    135                    140

10 Ser Asn Thr Lys Cys Lys Glu Glu Gly Ser Arg Ser Asn

145                    150                    155

15 Sequence ID No.: 16

Sequence Length: 2534

20 Sequence Type: nucleic acid

Molecular Type: cDNA to mRNA

Sequence:

25 GACGCTTCTG GGGAGTGAGG GAAGCGGTTT ACGAGTGA CTGCTGGAGC CTCAGGGGCG 60

GGCACTGGCA CGGAACACAC CCTGAGGCCA GCCCTGGCTG CCCAGGCGGA GCTGCCTCTT 120

30 CTCCCGCGGG TTGGTGGACC CGCTCAGTAC GGAGTTGGGG AAGCTCTTTC ACTTCGGAGG 180

ATTGCTCAAC AACCATGCTG GGCATCTGGA CCCTCCTACC TCTGGTTCTT ACGTCTGTTG 240

CTAGATTATC GTCCAAAAGT GTTAATGCCC AAGTGACTGA CATCAACTCC AAGGGATTGG 300

35 AATTGAGGAA GACTGTTACT ACAGTTGAGA CTCAGAACTT GGAAGGCCTG CATCATGATG 360

GCCAATTCTG CCATAAGCCC TGTCTCCAG GTGAAAGGAA AGCTAGGGAC TGCACAGTCA 420

40 ATGGGGATGA ACCAGACTGC GTGCCCTGCC AAGAAGGGAA GGAGTACACA GACAAAGCCC 480

ATTTTCTTTC CAAATGCAGA AGATGTAGAT TGTGTGATGA AGGACATGGC TTAGAAGTGG 540

AAATAAACTG CACCCGGACC CAGAATACCA AGTGCAGATG TAAACCAAAC TTTTGTGTA 600

45 ACTCTACTGT ATGTGAACAC TGTGACCCTT GCACCAAATG TGAACATGGA ATCATCAAGG 660

AATGCACACT CACCAGCAAC ACCAAGTGCA AAGAGGAAGG ATCAGATCT AACTTGGGGT 720

50 GGCTTTGTCT TCTTCTTTTG CCAATTCAC TAATGTGTTG GGTGAAGAGA AAGGAAGTAC 780

AGAAAACATG CAGAAAGCAC AGAAAGGAAA ACCAAGGTTT TCATGAATCT CCAACCTTAA 840

55

ATCCTGAAAC AGTGGCAATA AATTTATCTG ATGTTGACTT GAGTAAATAT ATCACCCTA 900  
 5 -TTGCTGGAGT CATGACACTA AGTCAAGTTA AAGGCTTTGT TCGAAAGAAT GGTGTCAATG 960  
 AAGCCAAAAT AGATGAGATC AAGAATGACA ATGTCCAAGA CACAGCAGAA CAGAAAGTTC 1020  
 AACTGCTTCG TAATTGGCAT CAACTTCATG GAAAGAAAGA AGCGTATGAC ACATTGATTA 1080  
 10 AAGATCTCAA AAAAGCCAAT CTTTGTACTC TTGCAGAGAA AATTCAGACT ATCATCCTCA 1140  
 AGGACATTAC TAGTGACTCA GAAAATTCAA ACTTCAGAAA TGAAATCCAA AGCTTGGTCT 1200  
 AGAGTGAAAA ACAACAAATT CAGTTCTGAG TATATGCAAT TAGTGTTTGA AAAGATTCTT 1260  
 15 AATAGCTGGC TGTAAATACT GCTTGGTTTT TTAGTGGGTA CATTTTATCA TTTATTAGCG 1320  
 CTGAAGAGCC AACATATTTG TAGATTTTAA ATATCTCATG ATTCTGCCTC CAAGGATGTT 1380  
 20 TAAAATCTAG TTGGGAAAAC AAACCTCATC AAGAGTAAAT GCAGTGGCAT GCTAAGTACC 1440  
 CAAATAGGAG TGTATGCAGA GGATGAAAGA TTAAGATTAT GCTCTGGCAT CTAACATATG 1500  
 ATTCTGTAGT ATGAATGTAA TCAGTGTATG TTAGTACAAA TGTCTATCCA CAGGCTAACC 1560  
 25 CCACTCTATG AATCAATAGA AGAAGCTATG ACCTTTTGCT GAAATATCAG TTAGTGAACA 1620  
 GGCAGGCCAC TTGCTCTA AATTACCTCT GATAATTCTA GAGATTTTAC CATATTTCTA 1680  
 30 AACTTTGTTT ATAACCTCTGA GAAGATCATA TTTATGTAAA GTATATGTAT TTGAGTGCAG 1740  
 AATTAAATA AGGCTCTACC TCAAAGACCT TTGCACAGTT TATTGGTGTC ATATTATACA 1800  
 ATATTTCAAT TGTGAATTCA CATAGAAAAC ATTAAATTAT AATGTTTGAC TATTATATAT 1860  
 35 GTGTATGCAT TTTACTGGCT CAAAACCTACC TACTTCTTTC TCAGGCATCA AAAGCATTTT 1920  
 GAGCAGGAGA GTATTACTAG AGCTTTGCCA CCTCTCCATT TTTGCCTTGG TGCTCATCTT 1980  
 40 AATGGCTTAA TGCACCCCA AACATGGAAA TATCACCAA AAATACTTAA TAGTCCACCA 2040  
 AAAGGCAAGA CTGCCCTTAG AAATTCTAGC CTGGTTTGA GATACTAACT GCTCTCAGAG 2100  
 AAAGTAGCTT TGTGACATGT CATGAACCA TGTGTGCAAT CAAAGATGAT AAAATAGATT 2160  
 45 CTTATTTTTC CCCACCCCC GAAATGTTC AATAATGTCC CATGTAAAAC CTGCTACAAA 2220  
 TGGCAGCTTA TACATAGCAA TGGTAAAATC ATCATCTGGA TTTAGGAATT GCTCTTGTC 2280  
 50 TACCCTCAAG TTTCTAAGAT TTAAGATTCT CCTTACTACT ATCCTACGTT TAAATATCTT 2340  
 TGAAAGTTTG TATTAATGT GAATTTTAAG AAATAATATT TATATTTCTG TAAATGTAAA 2400

CTGTGAAGAT AGTTATAAAC TGAAGCAGAT ACCTGGAACC ACCTAAAGAA CTTCCATTTA 2460  
5 TGGAGGATTT TTTTGGCCCT TGTGTTTGA ATTATAAAAT ATAGGTAAAA GTACGTAATT 2520  
AAATAATGTT TTTG 2534

10 Sequence ID No.: 17

Sequence Length: 486

15 Sequence Type: nucleic acid

Molecular Type: cDNA to mRNA)

Sequence:

20 TTTTCTTCCA TTTCAGGTGT CGTGAGGAAT TCACCATGCT GGGCATCTGG ACCCTCCTAC 60  
CTCTGGTTCT GACTAGTGTC GCTACTCAGA ACTTGAAGG CCTGCATCAT GATGGCCAAT 120  
TCTGCCATAA GCCCTGTCCT CCAGGTGAAA GGAAAGCTAG GGACTGCACA GTCAATGGGG 180  
25 ATGAACCAGA CTGCGTGCCC TGCCAAGAAG GGAAGGAGTA CACAGACAAA GCCCATTTTT 240  
CTTCCAAATG CAGAAGATGT AGATTGTGTG ATGAAGGACA TGGCTTAGAA GTGGAAATAA 300  
30 ACTGCACCGG GACCCAGAAT ACCAAGTGCA GATGTAAACC AAACITTTTT TGTAACCTA 360  
CTGTATGTGA AACTGTGAC CCTTGCACCA AATGTGAACA TGGAATCATC AAGGAATGCA 420  
CACTCACCAG CAACACCAAG TGCAAAGAGG AAGGATCCAG ATCTAACTAA TAGGGTACCT 480  
35 TCTGAG 486

40 Sequence ID No.: 18

Sequence Length: 1182

Sequence Type: nucleic acid

45 Molecular Type: cDNA to mRNA

Sequence:

50 TTTTCTTCCA TTTCAGGTGT CGTGAGGAAT TCACCATGCT GGGCATCTGG ACCCTCCTAC 60  
CTCTGGTTCT GACTAGTGTC GCTACTCAGA ACTTGAAGG CCTGCATCAT GATGGCCAAT 120

TCTGCCATAA GCCCTGTCCT CCAGGTGAAA GGAAAGCTAG GGACTGCACA GTCAATGGGG 180  
5 ATGAACCAGA CTGCGTGCCC TGCCAAGAAG GGAAGGAGTA CACAGACAAA GCCCATTTTT 240  
CTTCCAAATG CAGAAGATGT AGATTGTGTG ATGAAGGACA TGGCTTAGAA GTGGAAATAA 300  
ACTGCACCCG GACCCAGAAT ACCAAGTGCA GATGTAAACC AAACTTTTTT TGTAACCTCTA 360  
10 CTGTATGTGA ACACTGTGAC CCTTGCACCA AATGTGAACA TGGAATCATC AAGGAATGCA 420  
CACTCACCAG CAACACCAAG TGCAAAGAGG AAGGATCCAG ATCTAACGAG CCCAAATCTT 480  
GTGACAAAAC TCACACATGC CCACCGTGCC CAGCACCTGA ACTCCTGGGG GGACCGTCAG 540  
15 TCTTCCTCTT CCCCCAAAA CCCAAGGACA CCCTCATGAT CTCCGGGACC CCTGAGGTCA 600  
CATGCGTGGT GGTGGACGTG AGCCACGAAG ACCCTGAGGT CAAGTTCAAC TGGTACGTGG 660  
20 ACGGCGTGGA GGTGCATAAT GCCAAGACAA AGCCGCGGGA GGAGCAGTAC AACAGCACGT 720  
ACCGTGTGGT CAGCGTCCTC ACCGTCTGC ACCAGGACTG GCTGAATGGC AAGGAGTACA 780  
AGTGCAAGGT CTCCAACAAA GCCCTCCCAG CCCCATCGA GAAAACCATC TCCAAAGCCA 840  
25 AAGGGCAGCC CCGAGAACCA CAGGTGTACA CCCTGCCGCC ATCCCGGGAT GAGCTGACCA 900  
AGAACCAGGT CAGCCTGACC TGCTGGTCA AAGGCTTCTA TCCCAGCGAC ATCGCCGTGG 960  
30 AGTGGGAGAG CAATGGGCAG CCGGAGAACA ACTACAAGAC CACGCCTCCC GTGCTGGACT 1020  
CCGACGGCTC CTTCTTCCTC TACAGCAAGC TCACCGTGGA CAAGAGCAGG TGGCAGCAGG 1080  
GGAACGTCTT CTCATGCTCC GTGATGCATG AGGCTCTGCA CAACCACTAC ACGCAGAAGA 1140  
35 GCCTCTCCCT GTCTCCGGGT AAATGATAGG GTACCTTCTG AG 1182

Sequence ID No.: 19

Sequence Length: 531

Sequence Type: nucleic acid

Molecular Type: cDNA to mRNA

Sequence:

TTTTCTTCCA TTTCAGGTGT CGTGAGGAAT TCACCATGCT GGGCATCTGG ACCCTCCTAC 60  
50 CTCTGGTCTT GACTAGTGTC GCTACTCAGA ACTTGAAGG CCTGCATCAT GATGGCCAAT 120

TCTGCCATAA GCCCTGTCTT CCAGGTGAAA GGAAAGCTAG GGACTGCACA GTCAATGGGG 180  
 5 ATGAACCAGA CTGCGTGCCC TGCCAAGAAG GGAAGGAGTA CACAGACAAA GCCCATTTTT 240  
 CTTCCAAATG CAGAAGATGT AGATTGTGTG ATGAAGGACA TGGCTTAGAA GTGGAATAA 300  
 ACTGCACCCG GACCCAGAAT ACCAAGTGCA GATGTAAACC AAACTTTTTT TGTAACCTTA 360  
 10 CTGTATGTGA AACTGTGAC CCTTGACCA AATGTGAACA TGGAATCATC AAGGAATGCA 420  
 CACTCACCAG CAACACCAAG TGCAAGAGG AAGGATCCAG ATCTAACGAG CCCAAATCTT 480  
 15 GTGACAAAAC TCACACATGC CCACCGTGCC CATAGTGAGG TACCTTCTGA G 531

20

### Claims

1. A novel Fas antigen derivative which comprises at least a part or entire portion of Fas antigen extracellular region polypeptide in which at least one amino acid residue is deleted from a group of amino acid residues starting from the N-terminal amino acid residue of the Fas antigen polypeptide to a cysteine residue most close to the N-terminal side (excluding said cysteine residue).
2. The novel Fas antigen derivative according to claim 1 wherein said Fas antigen extracellular region polypeptide in which at least one amino acid residue is deleted is a Fas antigen extracellular region polypeptide in which at least one amino acid residue is deleted from the 1st to 42nd amino acid residues counting from the N-terminus of the Sequence ID No. 15 in the Sequence Listing.
3. The novel Fas antigen derivative according to claim 1 or 2 wherein the number of deleted amino acid residues in said Fas antigen extracellular region polypeptide from which amino acid residues are deleted is 29 or more.
4. The novel Fas antigen derivative according to any one of claims 1 to 3 wherein it is
  - a polypeptide comprising a part or entire portion of Fas antigen extracellular region polypeptide in which at least one amino acid residue is deleted from a group of amino acid residues starting from the N-terminal amino acid residue of the Fas antigen polypeptide to a cysteine residue most close to the N-terminal side (excluding said cysteine residue)
  - or,
  - a novel Fas antigen variant comprising 1 or 2 or more parts of Fas antigen, which include at least said polypeptide and are further selected from the group consisting of polypeptides that contain a part or entire portion of Fas antigen transmembrane region and/or Fas antigen cytoplasmic tail region.
5. The novel Fas antigen derivative according to any one of claims 1 to 3 wherein it is a fusion polypeptide which contains the novel Fas antigen variant disclosed in claim 4 and a (poly)peptide other than the Fas antigen.
6. The novel Fas antigen derivative according to claim 5 wherein it contains at least one (poly)peptide selected from the group consisting of the following substances a and b, which is contained in the C-terminal side of the fusion protein disclosed in claim 5,
  - a. a part or entire portion of the hinge region of immunoglobulin, and
  - b. a part or entire portion of the Fc fragment of immunoglobulin.
7. A novel Fas antigen derivative which is a polymer of any one of the novel Fas antigen derivatives disclosed in claims 1 to 6.

8. A DNA fragment which comprises a DNA sequence coding for any one of the polypeptides disclosed in claims 1 to 7.
9. The DNA fragment according to claim 8 wherein it contains any one of the DNA sequences shown in the Sequence ID Nos. 12 to 14 of the Sequence Listing.
10. A recombinant DNA molecule which comprises the DNA sequence disclosed in claim 8 or 9.
11. A transformant which is transformed with the recombinant DNA molecule of claim 10.
12. A method for producing the novel Fas antigen derivative of any one of claims 1 to 7, which comprises the steps of culturing the transformant of claim 11 and recovering and purifying the novel Fas antigen derivative of any one of claims 1 to 7 from said culture mixture.
13. A medicament which comprises the novel Fas antigen derivative of any one of claims 1 to 7 or a physiologically acceptable salt thereof as its active ingredient.
14. A method for improving activity or function of Fas antigen or a Fas antigen derivative, which comprises deleting at least one of the amino acid residues starting from the N-terminal amino acid residue of the Fas antigen to a cysteine residue most close to the N-terminal side (excluding said cysteine residue).

---

**THIS PAGE BLANK (USPTO)**

---



FIG. 1 - 1

GACGCTTCTGGGGAGTGAGGGAAGCGGTTTACGAGTGAAGTTC

50

100

GCTGGAGGCTCAGGGGGGGGCACTGGCACGGAACACACCCTGAGGCCAGCCCTGGCTGCCCAGGCGGAGCTGCCTC

150

TTCTCCCGCGGGTTGCTGGACCCGCTCAGTACGGAGTTGGGGAAGCTCTTTCACTTCGGAGGATTGCTCAACAACC

200

250

ATG CTG GGC ATC TGG ACC CTC CTA CCT CTG GTT CTT ACG TCT GTT GCT AGA TTA TCG

Met Leu Gly Ile Trp Thr Leu Leu Pro Leu Val Leu Thr Ser Val Ala Arg Leu Ser

-10

-1 +1

300

TCC AAA AGT GTT AAT GCC CAA CTG ACT GAC ATC AAC TCC AAG CGA TTG GAA TTG AGG

Ser Lys Ser Val Asn Ala Gln Val Thr Asp Ile Asn Ser Lys Gly Leu Glu Leu Arg

10

20

350

AAG ACT GTT ACT ACA GTT GAG ACT CAG AAC TTG GAA GGC CTG CAT CAT GAT GGC CAA

Lys Thr Val Thr Thr Val Glu Thr Gln Asn Leu Glu Gly Leu His His Asp Gly Gln

30

40

---

**THIS PAGE BLANK** (USPTO)

---

## F I G. 1 - 2

400

TTC TGC CAT AAG CCC TGT CCT CCA GGT GAA AGG AAA GCT AGG GAC TGC ACA GTC AAT  
 Phe Cys His Lys Pro Cys Pro Pro Gly Glu Arg Lys Ala Arg Asp Cys Thr Val Asn

50

60

450

GGG GAT GAA CCA GAC TGC GTG CCC TGC CAA GAA GGG AAG GAG TAC ACA GAC AAA GCC  
 Gly Asp Glu Pro Asp Cys Val Pro Cys Gln Glu Gly Lys Glu Tyr Thr Asp Lys Ala

70

500

CAT TTT TCT TCC AAA TGC AGA AGA TGT AGA TTG TGT GAT GAA GGA CAT GCC TTA GAA  
 His Phe Ser Ser Lys Cys Arg Arg Cys Arg Leu Cys Asp Glu Gly His Gly Leu Glu

80

90

550

GTG GAA ATA AAC TGC ACC CGG ACC CAG AAT ACC AAG TGC AGA TGT AAA CCA AAC TTT  
 Val Glu Ile Asn Cys Thr Arg Thr Gln Asn Thr Lys Cys Arg Cys Lys Pro Asn Phe

100

\*

110

600

650

TTT TGT AAC TCT ACT GTA TGT GAA CAC TGT GAC CCT TGC ACC AAA TGT GAA CAT GGA  
 Phe Cys Asn Ser Thr Val Cys Glu His Cys Asp Pro Cys Thr Lys Cys Glu His Gly

120

130

**THIS PAGE BLANK (USPTO)**

## FIG. 1 - 3

700

ATC ATC AAG GAA TGC ACA CTC ACC AGC AAC ACC AAG TGC AAA GAG GAA GGA TCC AGA  
 Ile Ile Lys Glu Cys Thr Leu Thr Leu Thr Ser Asn Thr Lys Glu Glu Gly Ser Arg

140

150

750

TCT AAC TTG GGG TGC CTT TCT CTT CTT CTT TTG CCA ATT CCA CTA ATT GTT TGG GTC  
 Ser Asn Leu Gly Trp Leu Cys Leu Leu Leu Leu Pro Ile Pro Leu Ile Val Trp Val

160

170

800

AAG AGA AAG GAA GTA CAG AAA ACA TGC AGA AAG CAC AGA AAG GAA AAC CAA GGT TCT  
 Lys Arg Lys Glu Val Gln Lys Thr Cys Arg Lys His Arg Lys Glu Asn Gln Gly Ser

180

190

850

CAT GAA TCT CCA ACC TTA AAT CCT GAA ACA GTG GCA ATA AAT TTA TCT CAT GTT GAC  
 His Glu Ser Pro Thr Leu Asn Pro Glu Thr Val Ala Ile Asn Leu Ser Asp Val Asp

200

210

900

TTG AGT AAA TAT ATC ACC ACT ATT GCT GCA GTC ATG ACA CTA AGT CAA GTT AAA GGC  
 Leu Ser Lys Tyr Ile Thr Thr Ile Ala Gly Val Met Thr Leu Ser Gln Val Lys Gly

220

230

**THIS PAGE BLANK (USPTO)**

---

FIG. 1 - 4

950

TTT GTT CGA AAG AAT GGT GTC AAT GAA GCC AAA ATA GAT GAG ATC AAG AAT GAC AAT  
Phe Val Arg Lys Asn Gly Val Asn Glu Ala Lys Ile Asp Glu Ile Lys Asn Asp Asn

240

250

1000

GTC CAA GAC ACA GCA GAA CAG AAA GTT CAA CTG CTT CGT AAT TGG CAT CAA CTT  
Val Gln Asp Thr Ala Glu Gln Lys Val Gln Leu Leu Arg Asn Trp His Gln Leu

260

1050

CAT GCA AAG AAA GAA GCG TAT GAC ACA TTG ATT AAA CAT CTC AAA AAA  
His Gly Lys Lys Glu Ala Tyr Asp Thr Leu Ile Lys Asp Leu Lys Lys

270

280

**THIS PAGE BLANK (USPTO)**



## FIG. 2 - 1

1100 1150  
GCC AAT CTT TGT ACT CTT GCA GAG AAA ATT CAG ACT ATC ATC CTC AAG GAC ATT ACT  
Ala Asn Leu Cys Thr Leu Ala Glu Lys Ile Gln Thr Ile Ile Leu Lys Asp Ile Thr  
290 300  
1200  
AGT GAC TCA GAA AAT TCA AAC TTC AGA AAT GAA ATC CAA AGC TTG CTC TAG ACTGAAA  
Ser Asp Ser Glu Asn Ser Asn Phe Arg Asn Glu Ile Gln Ser Leu Val End  
310  
1250  
AACAACAAATTCAGTTCTGAGTATATGCAATTAGTGTGTTGAAAAGATTCTTAATAGCTGGCTGTAAATACTGCTTG  
1300 1350  
GTTTTTTACTGGGTACATTTTATCATTTATTAGCCCTGAAGAGCCAACATATTTGTAGATTTTAAATATCTCATGA  
1400  
TTCTGCCTCCAAGCATCTTTAAATCTAGTTGGGAAAACAACTTCATCAAGAGTAAATGCAGTGGCATGCTAAGT  
1450 1500  
ACCCAAATAGGACTGTATGCAGACCATGAAAGATTAAGATTATGCTCTGGCATCTAACATATGATTCTGTAGTATC

---

**THIS PAGE BLANK (USPTO)**

---

FIG. 2 - 2

1550

AATGTAATCAGTGTATGTTACTACAAATGTCTATCCACAGGCTAACCCCACTCTATGAATCAATAGAAGAAGCTAT

1600

1650

GACCTTTTGCTGAAATATCAGTTACTGAACAGGCAGGCCACTTTGCCTCTAAATTACCTCTGATAATTCTAGAGAT

1700

TTTACCATATTTCTAAACTTTGTTTATAACTCTGAGAAGATCATATTTATGTAAAGTATATGTATTTGAGTGCAGA

1750

1800

ATTTAAATAAGGCTCTACCTCAAAGACCTTTGCACAGTTTATTGGTGTCAATTATACAATATTTCAATTGTGAAT

1850

TCACATAGAAAACATTAAATTATAATGTTTGACTATTATATATGTGTATGCATTTTACTGGCTCAAACTACCTAC

1900

1950

TTCTTTCTCAGGCATCAAAGCATTGACCAGGAGACTATTACTAGAGCTTTGCCACCTCTCCATTTTGCCTTC

**THIS PAGE BLANK (USPTO)**

FIG. 2 - 3

2000

GTGCTCATCTTAATGGCCTAATGCACCCCCAAACATGGAAATATCACCAAAAAATACTTAATAGTCCACCAAAAAGG

2050

2100

CAAGACTGCCCTTAGAAATTCTAGCCTGGTTTGGAGATACTAACTGCTCTCAGAGAAAGTAGCTTTGTGACATGTC

2150

ATGAACCCATGTTTGCAATCAAAGATGATAAAATAGATTCTTATTTTTCCCCACCCCCGAAAATCTTCAATAATG

2200

2250

TCCCATGTAAACCTGCTACAAATGCCAGCTTATACATACCAATGGTAAATCATCATCTGGATTAGGAATTG

2300

CTCTTGTCATACCCTCAAGTTTCTAAGATTTAAGATTCTCCTTACTACTATCCTACGTTTAAATATCTTTGAAACT

2350

2400

TTCTATTAAATGTGAATTTTAAGAAATAATATTTATTTCTGTAAATGTAAACTGTGAAGATAGTTATAAACT

**THIS PAGE BLANK (USPTO)**

FIG. 2 - 4

2450

GAAGCAGATACCTGGAACCACTAAAGAACTTCCATTTATGGAGGATTTTTTTGCCCTTGTCTTTGGAATTATAA

2500

AATATAGGTAAAACTACGTAATTAATAATGTTTTTC

**THIS PAGE BLANK (USPTO)**



FIG. 3-1

ttttcttccatttcaggtgtcgtgaggaattcacc

50

ATG	CTG	GGC	ATC	TGG	ACC	CTC	CTA	CCT	CTG
Met	Leu	Gly	Ile	Trp	Thr	Leu	Leu	Pro	Leu

hFas antigen signal peptide

-10

GTT	CTG	ACT	AGT	GTC	GCT	ACT	CAG	AAC	TTG
Val	Leu	Thr	Ser	Val	Ala	Thr	Gln	Asn	Leu

-1

1

100

hFas (nd29)

GAA	GGC	CTG	CAT	CAT	GAT	GGC	CAA	TTC	TGC
Glu	Gly	Leu	His	His	Asp	Gly	Gln	Phe	Cys

10

150

CAT	AAG	CCC	TGT	CCT	CCA	GGT	GAA	AGG	AAA
His	Lys	Pro	Cys	Pro	Pro	Gly	Glu	Arg	Lys

GCT	AGG	GAC	TGC	ACA	GTC	AAT	GGG	GAT	GAA
Ala	Arg	Asp	Cys	Thr	Val	Asn	Gly	Asp	Glu

200

CCA	GAC	TGC	GTG	CCC	TGC	CAA	GAA	GGG	AAG
Pro	Asp	Cys	Val	Pro	Cys	Gln	Glu	Gly	Lys

GAG	TAC	ACA	GAC	AAA	GCC	CAT	TTT	TCT	TCC
Glu	Tyr	Thr	Asp	Lys	Ala	His	Phe	Ser	Ser

50

250

AAA	TGC	AGA	AGA	TGT	AGA	TTG	TGT	GAT	GAA
Lys	Cys	Arg	Arg	Cys	Arg	Leu	Cys	Asp	Glu

---

**THIS PAGE BLANK (USPTO)**

---

FIG. 3 - 2

300  
 GGA CAT GGC TTA GAA GTG GAA ATA AAC TGC  
 Gly His Gly Leu Glu Val Glu Ile Asn Cys

\*

ACC CGG ACC CAG AAT ACC AAG TGC AGA TGT  
 Thr Arg Thr Gln Asn Thr Lys Cys Arg Cys

350  
 AAA CCA AAC TTT TTT TGT AAC TCT ACT GTA  
 Lys Pro Asn Phe Phe Cys Asn Ser Thr Val

\*

TGT GAA CAC TGT GAC CCT TGC ACC AAA TGT  
 Cys Glu His Cys Asp Pro Cys Thr Lys Cys  
 100

400  
 GAA CAT GGA ATC ATC AAG GAA TGC ACA CTC  
 Glu His Gly Ile Ile Lys Glu Cys Thr Leu

450  
 ACC AGC AAC ACC AAG TGC AAA GAG GAA GGA  
 Thr Ser Asn Thr Lys Cys Lys Glu Glu Gly

TCC AGA TCT AAC TAA TAG ggtaccttctgag  
 Ser Arg Ser Asn \*\*\* \*\*

**THIS PAGE BLANK (USPTO)**

FIG. 4-1

ttttcttccatttcaggtgtcgtgaggaattcacc  
50

ATG	CTG	GGC	ATC	TGG	ACC	CTC	CTA	CCT	CTG
Met	Leu	Gly	Ile	Trp	Thr	Leu	Leu	Pro	Leu

-10

hFas antigen signal peptide

GTT	CTG	ACT	AGT	GTC	GCT	ACT	CAG	AAC	TTG
Val	Leu	Thr	Ser	Val	Ala	Thr	Gln	Asn	Leu

-1

1

100

→ hFas (nd29)

GAA GGC CTG CAT CAT GAT GGC CAA TTC TGC  
Glu Gly Leu His His Asp Gly Gln Phe Cys

150

CAT AAG CCC TGT CCT CCA GGT GAA AGG AAA  
His Lys Pro Cys Pro Pro Gly Glu Arg Lys

GCT AGG GAC TGC ACA GTC AAT GGG GAT GAA  
Ala Arg Asp Cys Thr Val Asn Gly Asp Glu

200

CCA GAC TGC GTG CCC TGC CAA GAA GGG AAG  
Pro Asp Cys Val Pro Cys Gln Glu Gly Lys

GAG TAC ACA GAC AAA GCC CAT TTT TCT TCC  
Glu Tyr Thr Asp Lys Ala His Phe Ser Ser

50

250

AAA TGC AGA AGA TGT AGA TTG TGT GAT GAA  
Lys Cys Arg Arg Cys Arg Leu Cys Asp Glu

**THIS PAGE BLANK (USPTO)**

FIG. 4-2

300  
 GGA CAT GGC TTA GAA GTG GAA ATA AAC TGC  
 Gly His Gly Leu Glu Val Glu Ile Asn Cys  
 \*  
 ACC CGG ACC CAG AAT ACC AAG TGC AGA TGT  
 Thr Arg Thr Gln Asn Thr Lys Cys Arg Cys  
 350  
 AAA CCA AAC TTT TTT TGT AAC TCT ACT GTA  
 Lys Pro Asn Phe Phe Cys Asn Ser Thr Val  
 \*  
 TGT GAA CAC TGT GAC CCT TGC ACC AAA TGT  
 Cys Glu His Cys Asp Pro Cys Thr Lys Cys  
 100  
 400  
 GAA CAT GGA ATC ATC AAG GAA TGC ACA CTC  
 Glu His Gly Ile Ile Lys Glu Cys Thr Leu  
 450  
 ACC AGC AAC ACC AAG TGC AAA GAG GAA GGA  
 Thr Ser Asn Thr Lys Cys Lys Glu Glu Gly  
 TCC AGA TCT AAC GAG CCC AAA TCT TGT GAC  
 Ser Arg Ser Asn Glu Pro Lys Ser Cys Asp  
 hIgG1 Fc  
 500  
 AAA ACT CAC ACA TGC CCA CCG TGC CCA GCA  
 Lys Thr His Thr Cys Pro Pro Cys Pro Ala

**THIS PAGE BLANK (USPTO)**



FIG. 4 - 3

CCT GAA CTC CTG GGG GGA CCG TCA GTC TTC  
 Pro Glu Leu Leu Gly Gly Pro Ser Val Phe  
 150

550

CTC TTC CCC CCA AAA CCC AAG GAC ACC CTC  
 Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu

600

ATG ATC TCC CGG ACC CCT GAG GTC ACA TGC  
 Met Ile Ser Arg Thr Pro Glu Val Thr Cys

GTG GTG GTG GAC GTG AGC CAC GAA GAC CCT  
 Val Val Val Asp Val Ser His Glu Asp Pro

650

GAG GTC AAG TTC AAC TGG TAC GTG GAC GGC  
 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly

GTG GAG GTG CAT AAT GCC AAG ACA AAG CCG  
 Val Glu Val His Asn Ala Lys Thr Lys Pro  
 200

700

CGG GAG GAG CAG TAC AAC AGC ACG TAC CGT  
 Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg

750

GTG GTC AGC GTC CTC ACC GTC CTG CAC CAG  
 Val Val Ser Val Leu Thr Val Leu His Gln

---

**THIS PAGE BLANK (USPTO)**

FIG. 4-4

GAC TGG CTG AAT GGC AAG GAG TAC AAG TGC  
 Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys

800

AAG GTC TCC AAC AAA GCC CTC CCA GCC CCC  
 Lys Val Ser Asn Lys Ala Leu Pro Ala Pro

ATC GAG AAA ACC ATC TCC AAA GCC AAA GGG  
 Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly  
 250

850

CAG CCC CGA GAA CCA CAG GTG TAC ACC CTG  
 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu

900

CCC CCA TCC CGG GAT GAG CTG ACC AAG AAC  
 Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn

CAG GTC AGC CTG ACC TGC CTG GTC AAA GGC  
 Gln Val Ser Leu Thr Cys Leu Val Lys Gly

950

TTC TAT CCC AGC GAC ATC GCC GTG GAG TGG  
 Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp

GAG AGC AAT GGG CAG CCG GAG AAC AAC TAC  
 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr

300

**THIS PAGE BLANK (USPTO)**

FIG. 4-5

1000

AAG ACC ACG CCT CCC GTG CTG GAC TCC GAC  
 Lys Thr Thr Pro Pro Val Leu Asp Ser Asp

1050

GGC TCC TTC TTC CTC TAC AGC AAG CTC ACC  
 Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr

GTG GAC AAG AGC AGG TGG CAG CAG GGG AAC  
 Val Asp Lys Ser Arg Trp Gln Gln Gly Asn

1100

GTC TTC TCA TGC TCC GTG ATG CAT GAG GCT  
 Val Phe Ser Cys Ser Val Met His Glu Ala

CTG CAC AAC CAC TAC ACG CAG AAG AGC CTC  
 Leu His Asn His Tyr Thr Gln Lys Ser Leu

350

1150

TCC CTG TCT CCG GGT AAA TGA TAG ggtacc  
 Ser Leu Ser Pro Gly Lys \*\*\* \*\*\*

ttctgag

**THIS PAGE BLANK (USPTO)**

FIG. 5 - !

ttttcttccatttcaggtgtcgtgaggaattcacc

50

ATG	CTG	GGC	ATC	TGG	ACC	CTC	CTA	CCT	CTG
Met	Leu	Gly	Ile	Trp	Thr	Leu	Leu	Pro	Leu

-10

hFas antigen signal peptide

GTT	CTG	ACT	AGT	GTC	GCT	ACT	CAG	AAC	TTG
Val	Leu	Thr	Ser	Val	Ala	Thr	Gln	Asn	Leu

-1

1

100

hFas (nd29)

GAA	GGC	CTG	CAT	CAT	GAT	GGC	CAA	TTC	TGC
Glu	Gly	Leu	His	His	Asp	Gly	Gln	Phe	Cys

150

CAT	AAG	CCC	TGT	CCT	CCA	GGT	GAA	AGG	AAA
His	Lys	Pro	Cys	Pro	Pro	Gly	Glu	Arg	Lys

GCT	AGG	GAC	TGC	ACA	GTC	AAT	GGG	GAT	GAA
Ala	Arg	Asp	Cys	Thr	Val	Asn	Gly	Asp	Glu

200

CCA	GAC	TGC	GTG	CCC	TGC	CAA	GAA	GGG	AAG
Pro	Asp	Cys	Val	Pro	Cys	Gln	Glu	Gly	Lys

GAG	TAC	ACA	GAC	AAA	GCC	CAT	TTT	TCT	TCC
Glu	Tyr	Thr	Asp	Lys	Ala	His	Phe	Ser	Ser

50

250

AAA	TGC	AGA	AGA	TGT	AGA	TTG	TGT	GAT	GAA
Lys	Cys	Arg	Arg	Cys	Arg	Leu	Cys	Asp	Glu

**THIS PAGE BLANK (USPTO)**



FIG. 5-2

300  
 GGA CAT GGC TTA GAA GTG GAA ATA AAC TGC  
 Gly His Gly Leu Glu Val Glu Ile Asn Cys  
 \*  
 ACC CGG ACC CAG AAT ACC AAG TGC AGA TGT  
 Thr Arg Thr Gln Asn Thr Lys Cys Arg Cys  
 350  
 AAA CCA AAC TTT TTT TGT AAC TCT ACT GTA  
 Lys Pro Asn Phe Phe Cys Asn Ser Thr Val  
 \*  
 TGT GAA CAC TGT GAC CCT TGC ACC AAA TGT  
 Cys Glu His Cys Asp Pro Cys Thr Lys Cys  
 100  
 400  
 GAA CAT GGA ATC ATC AAG GAA TGC ACA CTC  
 Glu His Gly Ile Ile Lys Glu Cys Thr Leu  
 450  
 ACC AGC AAC ACC AAG TGC AAA GAG GAA GGA  
 Thr Ser Asn Thr Lys Cys Lys Glu Glu Gly  
 TCC AGA TCT AAC GAG CCC AAA TCT TGT GAC  
 Ser Arg Ser Asn Glu Pro Lys Ser Cys Asp  
 → hIgG1 hinge  
 500  
 AAA ACT CAC ACA TGC CCA CCG TGC CCA TAG  
 Lys Thr His Thr Cys Pro Pro Cys Pro \*\*\*


**THIS PAGE BLANK (USPTO)**

FIG. 5-3

TGA ggtaccttctgag  
\*\*\*

**THIS PAGE BLANK (USPTO)**

FIG. 6



(Non-reducing condition)

Lane 1 ~ 3 : s h F a s ( n d 2 9 ) - F c

Lane 4 : h F a s - F c


(Reducing condition)

Lane 5 ~ 7 : s h F a s ( n d 2 9 ) - F c

Lane 8 : h F a s - F c

**THIS PAGE BLANK (USPTO)**

FIG. 7




L a n e 1 : non-reducing condition  
L a n e 2 : reducing condition

**THIS PAGE BLANK (USPTO)**



FIG. 8



(Non-reducing condition)

L a n e 1 : sample befor gel filtration separation

L a n e 2 : fraction 1

L a n e 3 : fraction 2


L a n e 4 : fraction 3

L a n e 5 : fraction 4

**THIS PAGE BLANK (USPTO)**

**THIS PAGE BLANK (USPTO)**

FIG. 9



**THIS PAGE BLANK (USPTO)**

FIG. 10








FIG. 11



**THIS PAGE BLANK (USPTO)**




FIG. 12




**THIS PAGE BLANK (USPTO)**

FIG. 13

GOT and GPT after 8 hours (average  $\pm$  standard deviation)



GOT and GPT after 24 hours (average  $\pm$  standard deviation)




**THIS PAGE BLANK (USPTO)**


**BEST AVAILABLE COPY**

FIG. 14

GOT and GPT after 8 hours (average  $\pm$  standard deviation)




GOT and GPT after 24 hours (average  $\pm$  standard deviation)



**THIS PAGE BLANK (USPTO)**

**BEST AVAILABLE COPY**

FIG. 15



**THIS PAGE BLANK (U.S.P.C.)**

**BEST AVAILABLE COPY**



**THIS PAGE BLANK (USPTO)**

**BEST AVAILABLE COPY**

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP97/01502

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	JP, 5-503009, A (Genentech Inc.), May 27, 1993 (27. 05. 93) & EP, 526452, A & WO, 9108298, A	5 - 7
A	Eur. J. Immunol. 24 1994 David H. Lynch et al. "gld/gld mice are unable to express a functional ligand for Fas" p. 928-933	1 - 14
Y	"Nikkei Baio Saishin-Yogo Jiten '91 (in Japanese)" edited by Nikkei Baioteku (Nikkei BP sha) 1991, p. 550	1 - 14

**THIS PAGE BLANK (USPTO)**

**BEST AVAILABLE COPY**

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP97/01502

## A. CLASSIFICATION OF SUBJECT MATTER

Int. Cl<sup>6</sup> C12N15/12, C12N15/62, C07K14/47, C12P21/02, C12N1/21, A61K38/16

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Int. Cl<sup>6</sup> C12N15/12, C12N15/62, C07K14/47, C12P21/02, C12N1/21, A61K38/16

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS ONLINE, BIOSIS, WPI/WPI,L

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Cell 66 1991 Naoto Itoh et al. "The Polypeptide Encoded by the cDNA for Human Cell Surface Antigen Fas Can Mediate Apoptosis" p. 233-243	1 - 14
Y	The EMBO J. 14(6) 1995 Masato Tanaka et al. "Expression of the functional soluble form of human Fas ligand in activated lymphocytes" p. 1129-1135	1 - 14
Y	WO, 9513293, A (Mochida Pharmaceutical Co., Ltd.), May 18, 1995 (18. 05. 95) & EP, 675200, A & JP, 8-127594, A	1 - 14
A	JP, 7-289266, A (Mochida Pharmaceutical Co., Ltd.), November 7, 1995 (07. 11. 95) (Family: none)	1 - 14
Y	JP, 7-69914, A (Bristol-Myers Squibb Co.), March 14, 1995 (14. 03. 95) & EP, 613944, A	5 - 7

☒ Further documents are listed in the continuation of Box C.☐ See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&amp;" document member of the same patent family

Date of the actual completion of the international search

July 24, 1997 (24. 07. 97)

Date of mailing of the international search report

August 5, 1997 (05. 08. 97)

Name and mailing address of the ISA/

Japanese Patent Office

Authorized officer

Facsimile No.

Telephone No.